BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49:S45-55. [PMID: 19399792 DOI: 10.1002/hep.22898] [Cited by in Crossref: 515] [Cited by in F6Publishing: 477] [Article Influence: 36.8] [Reference Citation Analysis]
Number Citing Articles
1 Yost CC, Jimenez DC, Weber MP, Maynes EJ, Belden KA, Tchantchaleishvili V, Massey HT, Sass DA, Rame JE, Zurlo JJ, Aburjania N. Hepatitis B in Heart Transplant Donors and Recipients: A Systematic Review and Meta-Analysis. Journal of Surgical Research 2023;283:1078-1090. [DOI: 10.1016/j.jss.2022.10.078] [Reference Citation Analysis]
2 Teng J, Du Y, Visalath P, Zhou T, Du B, Zhang Q, Cai W. A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT. Virol J 2023;20:7. [PMID: 36631824 DOI: 10.1186/s12985-023-01963-x] [Reference Citation Analysis]
3 Harris AM, Schillie S. Hepatitis B and Hepatitis D Viruses. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00213-5] [Reference Citation Analysis]
4 Kirino S, Tamaki N, Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 2023;53:35-42. [PMID: 36117296 DOI: 10.1111/hepr.13839] [Reference Citation Analysis]
5 Sausen DG, Shechter O, Bietsch W, Shi Z, Miller SM, Gallo ES, Dahari H, Borenstein R. Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus. Int J Mol Sci 2022;23. [PMID: 36555623 DOI: 10.3390/ijms232415973] [Reference Citation Analysis]
6 Liu W, Dong Z, Hu W, Li K, Sun L, Hou J, Jia S, Liu Y. Trends in hepatitis B notification rates in Guangzhou, China, between 2009 and 2020: an epidemiological study. BMC Infect Dis 2022;22:913. [PMID: 36476118 DOI: 10.1186/s12879-022-07690-y] [Reference Citation Analysis]
7 Boccalini S, Bonito B, Zanella B, Liedl D, Bonanni P, Bechini A. The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile. Int J Environ Res Public Health 2022;19. [PMID: 36498435 DOI: 10.3390/ijerph192316365] [Reference Citation Analysis]
8 Sun X, Fu H, Wang C, Zhang Y, Han W, Chen H, Wang Y, Chen Q, He Y, Huang Q, Yan C, Chen Y, Han T, Lv M, Mo X, Wang J, Wang F, Chen Y, Zhu X, Xu L, Liu K, Huang X, Zhang X. Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection. Bone Marrow Transplant 2022. [DOI: 10.1038/s41409-022-01880-7] [Reference Citation Analysis]
9 Kang CK, Brennan PN, Dillon JF. How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review. CIA 2022;Volume 17:1811-1820. [DOI: 10.2147/cia.s366255] [Reference Citation Analysis]
10 Wu S, Du X, Lou G, Yu S, Lai K, Qi J, Ni S, Chen Z, Chen F. Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection. BMC Infect Dis 2022;22:842. [DOI: 10.1186/s12879-022-07841-1] [Reference Citation Analysis]
11 Yang G, Wan P, Zhang Y, Tan Q, Qudus MS, Yue Z, Luo W, Zhang W, Ouyang J, Li Y, Wu J. Innate Immunity, Inflammation, and Intervention in HBV Infection. Viruses 2022;14:2275. [DOI: 10.3390/v14102275] [Reference Citation Analysis]
12 Bada FO, Stafford KA, Osawe S, Wilson E, Sam-agudu NA, Chen H, Abimiku A, Campbell JD. Factors associated with receipt of a timely infant birth dose of hepatitis B vaccine at a tertiary hospital in North-Central Nigeria. PLOS Glob Public Health 2022;2:e0001052. [DOI: 10.1371/journal.pgph.0001052] [Reference Citation Analysis]
13 Yao N, Fu S, Wu Y, Tian Z, Feng Y, Li J, Luo X, Yang Y, Ji F, Chen Y, Liu J, Zhao Y, Chen T. Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2022;101:1197-206. [PMID: 36082797 DOI: 10.1111/aogs.14448] [Reference Citation Analysis]
14 Sapmaz FP, Büyükturan G, Sakin YS, Kalkan İH, Atasoy P. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients? Medicine (Baltimore) 2022;101:e30488. [PMID: 36086763 DOI: 10.1097/MD.0000000000030488] [Reference Citation Analysis]
15 Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, Aly HH, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Goh Y, Ishii KJ, Yotsuyanagi H, Muramatsu M, Ishii K, Takahashi Y, Suzuki R, Akari H, Kato T. Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. Nat Commun 2022;13:5207. [PMID: 36064848 DOI: 10.1038/s41467-022-32910-z] [Reference Citation Analysis]
16 Turyadi, Witanto B, El-khobar KE, Parewangi ML, Rasyak MR, Wibowo DP, Thedja MD, Yusuf I, Massi MN, Patellongi I, Syafruddin D, Muljono DH, Fortofoiu M. Host Factors in the Natural History of Chronic Hepatitis B: Role of Genetic Determinants. International Journal of Hepatology 2022;2022:1-10. [DOI: 10.1155/2022/6046677] [Reference Citation Analysis]
17 Le LV, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, Sharma M, Mangadan-Konath N, Razavi H, Low-Beer D, Razavi-Shearer D. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting. Liver Int 2022;42:1930-4. [PMID: 34894047 DOI: 10.1111/liv.15131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jacobson IM, Brown RS Jr, McMahon BJ, Perrillo RP, Gish R. An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. J Clin Gastroenterol 2022;56:478-92. [PMID: 35389923 DOI: 10.1097/MCG.0000000000001695] [Reference Citation Analysis]
19 Liu S, Xu C, Yang F, Zong L, Qin Y, Gao Y, Su Q, Li T, Li Y, Xu Y, Zheng M. Natural Killer Cells Induce CD8+ T Cell Dysfunction via Galectin-9/TIM-3 in Chronic Hepatitis B Virus Infection. Front Immunol 2022;13:884290. [DOI: 10.3389/fimmu.2022.884290] [Reference Citation Analysis]
20 Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal 2022; 10(3): 99-121 [DOI: 10.13105/wjma.v10.i3.99] [Reference Citation Analysis]
21 Yang N, Lei L, Meng Y, Zhou N, Shi L, Hu M. Cost-Benefit Analysis of Vaccination Strategies to Prevent Mother-to-Child Transmission of the Hepatitis B Virus Using a Markov Model Decision Tree. Front Public Health 2022;10:662442. [DOI: 10.3389/fpubh.2022.662442] [Reference Citation Analysis]
22 Akbar SMF, Yoshida O, Hiasa Y. Immune therapies against chronic hepatitis B. J Gastroenterol 2022. [PMID: 35708793 DOI: 10.1007/s00535-022-01890-8] [Reference Citation Analysis]
23 Li J, Xu J, Wang Y, Li Q, Sun X, Fu W, Zhang B. Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population. Genet Test Mol Biomarkers 2022;26:255-62. [PMID: 35638911 DOI: 10.1089/gtmb.2021.0181] [Reference Citation Analysis]
24 Wang Y, Che Y, Wang S, Wang J, Liu X, Kou B, Guan Y, Chen D, Shi Y. ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study. Biochemical and Biophysical Research Communications 2022;610:61-9. [DOI: 10.1016/j.bbrc.2022.03.109] [Reference Citation Analysis]
25 Wang J, Zhang X, Geng X, Shi J, Jia X, Dang S, Wang W. Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. eClinicalMedicine 2022;48:101425. [DOI: 10.1016/j.eclinm.2022.101425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
27 Anderson ACT, Richards A, Delucchi K, Khalili M. Coverage, inequity and predictors of hepatitis B birth vaccination in Myanmar from 2011-2016: results from a national survey. BMC Health Serv Res 2022;22:516. [PMID: 35436953 DOI: 10.1186/s12913-022-07902-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ssuuna C, Ssempijja V, Kalibbala S, Serwadda D, Yeh PT, Wawer M, Gray R, Chang L, Kagaayi J, Reynolds S. Hepatitis B virus infection and factors associated with its acquisition among adults in a Lake Victoria HIV hyperendemic fishing community in Kyotera district, Uganda: a cross-sectional observation. BMJ Open 2022;12:e050436. [PMID: 35393306 DOI: 10.1136/bmjopen-2021-050436] [Reference Citation Analysis]
29 Zhou J, Guo X, Huang P, Tan S, Lin R, Zhan H, Wu X, Li T, Huang M, Huang M. HBV Infection Status Indicates Different Risks of Synchronous and Metachronous Liver Metastasis in Colorectal Cancer: A Retrospective Study of 3132 Patients with a 5-Year Follow-Up. CMAR 2022;Volume 14:1581-94. [DOI: 10.2147/cmar.s350276] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
31 Choi YH, Lee HW, Purdy MA. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 2022;12:4382. [PMID: 35288624 DOI: 10.1038/s41598-022-08457-w] [Reference Citation Analysis]
32 Lu M, Li J, Zhou Y, Rupp LB, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Trudeau S, Gordon SC; CHeCS Investigators. Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016). J Clin Gastroenterol 2022;56:273-9. [PMID: 33780209 DOI: 10.1097/MCG.0000000000001522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tadesse M, Tafesse G, Hajare ST, Chauhan NM. Assessment of Prevalence of Hepatitis B Virus and its Associated Factors among Pregnant Women from Wolaita Sodo, Ethiopia. Journal of Clinical Virology Plus 2022. [DOI: 10.1016/j.jcvp.2022.100069] [Reference Citation Analysis]
34 Chahal D, Lee JG, Yoshida EM, Lowe C, Ho F, Sum V, Kwan P. Seroprevalence of hepatitis B in previously undiagnosed patients: A community screening study. CanLivJ. [DOI: 10.3138/canlivj-2021-0008] [Reference Citation Analysis]
35 Calva-rodríguez R, Ruiz-arenas R, Ávila-ramírez C, Calva-ariza P, Rivera-domínguez ME, Coronel-cruzado L, Sánchez-rodríguez G. Niveles de anticuerpos contra hepatitis B en adolescentes: comparación de niños vacunados al nacer vs a los 12 meses de edad. Revista Mexicana de Pediatría 2022;89:36-39. [DOI: 10.35366/106859] [Reference Citation Analysis]
36 Cohen C, Evans AA, Block TM. Hepatitis Viruses: Hepatitis B and Hepatitis D. Viral Infections of Humans 2022. [DOI: 10.1007/978-1-4939-9544-8_32-1] [Reference Citation Analysis]
37 Meriki HD, Betterdel AN, Tufon KA, Shitebongnju PN. Effects of Hepatitis B Virus Co-Infection and Antiretroviral Therapy on Disease Progression among HIV Patients Treated at the Buea Regional Hospital, Southwest Region, Cameroon: A Case-Control Study. JBM 2022;10:253-272. [DOI: 10.4236/jbm.2022.109018] [Reference Citation Analysis]
38 Bergasa NV. Chronic Hepatitis B. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_7] [Reference Citation Analysis]
39 Zhang H, Zhao J, Yang W, Li Z, Gong L, Li Y. Liver Cancer: Interdisciplinary Approach. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_96] [Reference Citation Analysis]
40 Périères L, Diallo A, Marcellin F, Nishimwe ML, Ba EH, Coste M, Lo G, Halfon P, Touré Kane C, Maradan G, Carrieri P, Diouf A, Shimakawa Y, Sokhna C, Boyer S; ANRS 12356 AmBASS Survey Study Group. Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey). Hepatol Commun 2021. [PMID: 34918868 DOI: 10.1002/hep4.1879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wang Z, Yang X, Gui S, Yang F, Cao Z, Cheng R, Xia X, Li C. The Roles and Mechanisms of lncRNAs in Liver Fibrosis. Front Pharmacol 2021;12:779606. [PMID: 34899344 DOI: 10.3389/fphar.2021.779606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Bamias G, Pizarro TT, Cominelli F. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022;28:337-49. [PMID: 34904152 DOI: 10.1093/ibd/izab251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int 2021;41:2874-84. [PMID: 34297463 DOI: 10.1111/liv.15019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Netanel C, Ben-Aharon O, Ben-Ari Z, Chodick G, Anis E, Magnezi R. Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016. Vaccine 2021;39:7101-7. [PMID: 34782158 DOI: 10.1016/j.vaccine.2021.09.072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Périères L, Protopopescu C, Lo G, Marcellin F, Ba EH, Coste M, Touré Kane C, Diallo A, Sokhna C, Boyer S; ANRS 12356 AmBASS survey Study Group. Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: A cross-sectional survey. J Viral Hepat 2021;28:1515-25. [PMID: 34355470 DOI: 10.1111/jvh.13589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Zamor PJ, Lane AM. Interpretation of HBV Serologies. Clin Liver Dis 2021;25:689-709. [PMID: 34593148 DOI: 10.1016/j.cld.2021.06.012] [Reference Citation Analysis]
48 Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 2021; 27(36): 6053-6063 [PMID: 34629819 DOI: 10.3748/wjg.v27.i36.6053] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
50 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
52 Al-Busafi SA, Al-Harthi R, Al-Naamani K, Al-Zuhaibi H, Priest P. Risk Factors for Hepatitis B Virus Transmission 
in Oman. Oman Med J 2021;36:e287. [PMID: 34405055 DOI: 10.5001/omj.2021.99] [Reference Citation Analysis]
53 Riveiro-Barciela M, Marcos-Fosch C, Martinez-Valle F, Bronte F, Orozco O, Sanz-Pérez I, Torres D, Salcedo MT, Petta S, Esteban R, Craxi A, Buti M. Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World J Gastroenterol 2021; 27(30): 5112-5125 [PMID: 34497439 DOI: 10.3748/wjg.v27.i30.5112] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zhao X, Sun L, Mu T, Yi J, Ma C, Xie H, Liu M, Tang H. An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J Mol Cell Biol. 2020;12:263-276. [PMID: 31865380 DOI: 10.1093/jmcb/mjz104] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
55 Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. BMC Gastroenterol 2021;21:320. [PMID: 34372775 DOI: 10.1186/s12876-021-01892-5] [Reference Citation Analysis]
56 Kedar Mukthinuthalapati VVP, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, Abou-Alfa GK. Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Glob Oncol 2021;7:756-66. [PMID: 34043413 DOI: 10.1200/GO.20.00425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
57 Doi H, Kanto T. Factors influencing the durability of hepatitis B vaccine responses. Vaccine 2021;39:5224-30. [PMID: 34340855 DOI: 10.1016/j.vaccine.2021.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mudji J, Malala J, Horsmans Y. Seroprevalence of viral hepatitis B and C in two populations: blood donors and patients with suspected hepatic cirrhosis in Kwilu province, Democratic Republic of Congo. Int J Infect Dis 2021;110:222-5. [PMID: 34274508 DOI: 10.1016/j.ijid.2021.07.032] [Reference Citation Analysis]
59 Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol 2021; 27(26): 3971-3983 [PMID: 34326608 DOI: 10.3748/wjg.v27.i26.3971] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
60 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, Khalili M, Fontana RJ, Sterling RK, Terrault N, Feld JJ, Di Bisceglie AM, Lau DTY, Hassan M, Janssen HLA; Hepatitis B Research Network (HBRN). Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology 2021;73:2124-40. [PMID: 32936969 DOI: 10.1002/hep.31554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
64 Buti M, Marcos-Fosch C, Esteban R. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. Liver Int 2021;41 Suppl 1:9-14. [PMID: 34155802 DOI: 10.1111/liv.14848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Menner AS, Kinkel H, Dixit S, Morrison A, Rieke B, Küpper T. Prevalence and behavioural risk factors for hepatitis B in Upper Dolpo, Nepal. J Public Health (Berl ) 2021;29:481-488. [DOI: 10.1007/s10389-019-01152-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Wang H, Chen XZ, Chen XL, Zhang WH, Liu K, Wang YJ, Tang HR, Hu JK; SIGES research group. Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). Cancer Med 2021;10:3741-55. [PMID: 33934530 DOI: 10.1002/cam4.3901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Hamida ME, Raja SM, Seyoum Y, Elkhidir IM, Tekle F. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study. BMC Gastroenterol 2021;21:198. [PMID: 33933017 DOI: 10.1186/s12876-021-01789-3] [Reference Citation Analysis]
68 Das A, Kamrul-Hasan A, Kabir MR, Das S, Zaki K, Al Mahtab M. Evaluation of Chitinase 3-like 1 (CHI3L1) as a noninvasive biomarker of hepatic fibrosis in patients with Hepatitis B virus-related compensated chronic liver disease. J Family Med Prim Care 2021;10:1694-8. [PMID: 34123914 DOI: 10.4103/jfmpc.jfmpc_1922_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Abbas Z, Abbas M. Challenges in Formulation and Implementation of Hepatitis B Elimination Programs. Cureus 2021;13:e14657. [PMID: 33907651 DOI: 10.7759/cureus.14657] [Reference Citation Analysis]
70 El-Sayed MH, Said ZNA, Abo-Elmagd EK, Ebeid FSE, Salama II. High Risk of HBV Infection Among Vaccinated Polytransfused Children With Malignancy. J Pediatr Hematol Oncol 2021;43:e45-50. [PMID: 32769568 DOI: 10.1097/MPH.0000000000001887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Yao Y, Shen Y, Shao H, Liu Y, Ji Y, Du G, Ye X, Huang P, Chen H. Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population. J Med Virol 2021;93:4957-65. [PMID: 33783003 DOI: 10.1002/jmv.26969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, Vesin B, Lorin V, Hieu T, Stauffer A, Fiquet O, Dimitrov JD, Michel ML, Ungeheuer MN, Sureau C, Pol S, Di Santo JP, Strick-Marchand H, Pelletier N, Mouquet H. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med 2020;217:e20200840. [PMID: 32579155 DOI: 10.1084/jem.20200840] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
73 Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. [PMID: 33595662 DOI: 10.1001/jamanetworkopen.2020.37512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
74 Álvarez-payares JC, Álvarez-payares C, Restrepo-gutiérrez JC. Falla hepática aguda sobre crónica por exacerbación de hepatitis B asociada a suspensión de la terapia antiviral: reporte de caso. Hepatología 2021. [DOI: 10.52784/27112330.133] [Reference Citation Analysis]
75 Li H, Xu QY, Xie Y, Luo JJ, Cao HX, Pan Q. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis. Ann Hepatol 2021;24:100316. [PMID: 33515803 DOI: 10.1016/j.aohep.2021.100316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
76 Dündar Ök Z, Çelik M, Akbudak İH, Güleryüzlü Y, Yilmaz H, Yilmaz M. Kronik Hepatit B Tedavisinde HBSAG VE M30 Antijen Titre Takibinin Klinik Yararı. Pamukkale Medical Journal 2021. [DOI: 10.31362/patd.826929] [Reference Citation Analysis]
77 Wang L, Wu Z, Wang A, Jin X, Qiu Y. Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography. Nucl Med Commun 2020;41:314-9. [PMID: 31939901 DOI: 10.1097/MNM.0000000000001156] [Reference Citation Analysis]
78 Kwon JK, Artunduaga M, Gonzalez JD, Foust AM, Moredock EP, Görkem SB, Paltiel HJ. Liver. Pediatric Ultrasound 2021. [DOI: 10.1007/978-3-030-56802-3_11] [Reference Citation Analysis]
79 Yang H, Su T. Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_9] [Reference Citation Analysis]
80 Block PD, Shinn B, Kim JH, Hann HW. Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepat Oncol 2020;8:HEP35. [PMID: 33680431 DOI: 10.2217/hep-2020-0028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
81 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
82 Arnone OC, Serranti D, Bartolini E, Mastrangelo G, Stinco M, Trapani S, Ricci S, Resti M, Indolfi G. Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. J Viral Hepat 2020;27:1344-51. [PMID: 32853482 DOI: 10.1111/jvh.13382] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
83 Cho IY, Chang Y, Sung E, Sohn W, Kang JH, Shin H, Ryu S. Depressive symptoms and risk of liver-related mortality in individuals with hepatitis B virus infection: a cohort study. Sci Rep 2020;10:20812. [PMID: 33257781 DOI: 10.1038/s41598-020-77886-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Spearman CW. Chronic hepatitis B: identifying who needs to be treated and improving linkage to care. Lancet Gastroenterol Hepatol 2021;6:83-5. [PMID: 33197398 DOI: 10.1016/S2468-1253(20)30332-0] [Reference Citation Analysis]
85 Mahassadi AK, Team Machekam O, Attia AK. The Impact of Virologic Parameters and Liver Fibrosis on Health-Related Quality of Life in Black African Patients with Chronic Hepatitis B: Results from a High Endemic Area. Clin Exp Gastroenterol 2020;13:407-18. [PMID: 33061519 DOI: 10.2147/CEG.S255102] [Reference Citation Analysis]
86 Hamada-Tsutsumi S, Onishi M, Matsuura K, Isogawa M, Kawashima K, Sato Y, Tanaka Y. Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture. Int J Mol Sci 2020;21:E7251. [PMID: 33019495 DOI: 10.3390/ijms21197251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Li MR, Xu ZG, Lu JH, Zheng HW, Ye LH, Liu YY, Liu ZQ, Zhang HC, Huang Y, Dai EH, Pan CQ. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. J Viral Hepat 2020;27:1044-51. [PMID: 32384194 DOI: 10.1111/jvh.13315] [Reference Citation Analysis]
88 Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol 2019;10:e00036. [PMID: 31107725 DOI: 10.14309/ctg.0000000000000036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
89 Block P, Shinn B, Roth C, Needleman L, Rosato E, Hann H. Vagaries of the Host Response in the Development of Hepatitis B-related Hepatocellular Carcinoma: A Case Series. CCTR 2020;16:253-8. [DOI: 10.2174/1573394716666200129121051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
90 Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc 2021;120:847-53. [PMID: 32896456 DOI: 10.1016/j.jfma.2020.08.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
91 Hanson J, Fox M, Anderson A, Fox P, Webster K, Williams C, Nield B, Bagshaw R, Hempenstall A, Smith S, Solomon N, Boyd P. Chronic hepatitis B in remote, tropical Australia; successes and challenges. PLoS One 2020;15:e0238719. [PMID: 32881958 DOI: 10.1371/journal.pone.0238719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
92 Nicastro E, Mangili B, Giacomet V, Benincaso AR, Di Giorgio A, Sansotta N, Callegaro A, D'Antiga L. Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign-born Children With Chronic Hepatitis B. J Pediatr Gastroenterol Nutr 2020;71:381-7. [PMID: 32826716 DOI: 10.1097/MPG.0000000000002804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
93 Toyé RM, Lô G, Diop-Ndiaye H, Cissé AM, Ndiaye AJS, Kébé-Fall K, Dramé A, Cohen D, Pujol FH, Mboup S, Boye CS, Chemin I, Laborde-Balen G, Taverne B, Touré-Kane C. Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal. Clin Res Hepatol Gastroenterol 2021;45:101502. [PMID: 32828748 DOI: 10.1016/j.clinre.2020.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
94 Kachimanga C, Bangura M, Nyama E, Mhango M, Reed V, Rodriguez MP, Lado M. Screening and linkage to care for medical students with hepatitis B virus infection in Sierra Leone. Heliyon 2020;6:e04673. [PMID: 32802989 DOI: 10.1016/j.heliyon.2020.e04673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
95 Wu KL, Chen YL, Ko CJ, Lin PY, Chou CT. Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin-positive Mac-2-binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease. Exp Ther Med 2020;20:1953-60. [PMID: 32782504 DOI: 10.3892/etm.2020.8922] [Reference Citation Analysis]
96 Jiaming Z, Pinzhu H, Xiaoyan G, Shuyun T, Rongwan L, Huanmiao Z, Xiaofeng W, Yuanlv X, Mingzhe H, Hongen Y, Meijin H, Jianping W. HBV infection may reduce the risk of metachronous liver metastasis in postoperative pathological stage 2 colorectal cancer. Int J Colorectal Dis 2020;35:2205-17. [PMID: 32728919 DOI: 10.1007/s00384-020-03712-w] [Reference Citation Analysis]
97 Wu J, Mao W, Li X. Mean Platelet Volume/Lymphocyte Ratio as a Prognostic Indicator for HBV-Related Decompensated Cirrhosis. Gastroenterol Res Pract 2020;2020:4107219. [PMID: 32714387 DOI: 10.1155/2020/4107219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
98 Wu J, Mao W. Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases. Dis Markers 2020;2020:2471252. [PMID: 32774512 DOI: 10.1155/2020/2471252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Hsu YC, Huang YT. Editorial: risk assessment for chronic hepatitis B patients in the immune tolerant phase-both definition and selection matter. Aliment Pharmacol Ther 2020;52:213-4. [PMID: 32529769 DOI: 10.1111/apt.15798] [Reference Citation Analysis]
100 Khare S, Arora A, Sharma P, Dhawan S, Bansal N, Singla V, Kumar A. Performance of Non-invasive Blood Parameters for Ruling Out Significant Liver Fibrosis in Patients with Chronic Hepatitis B. J Clin Transl Hepatol 2020;8:143-9. [PMID: 32832394 DOI: 10.14218/JCTH.2020.00002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
101 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. Antiviral Res. 2020;179:104816. [PMID: 32387476 DOI: 10.1016/j.antiviral.2020.104816] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
103 Gan CJ, Li WF, Li CN, Li LL, Zhou WY, Peng XM. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochem Biophys Rep 2020;22:100763. [PMID: 32322693 DOI: 10.1016/j.bbrep.2020.100763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
104 Dai YN, Tu YX, Meng D, Chen MJ, Zhang JJ, Gong YH, Tong YX, Wang MS, Pan HY, Huang HJ. Serum Proteomic Changes as Candidate Biomarkers of Intermediate Liver Fibrosis in Chronic Hepatitis B Infection. OMICS 2019;23:167-79. [PMID: 30883302 DOI: 10.1089/omi.2018.0179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
105 Pisaturo M, Onorato L, Russo A, Chiodini P, Coppola N. An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. J Viral Hepat 2020;27:415-27. [PMID: 31834645 DOI: 10.1111/jvh.13248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
106 Azad AR, Zargar M, Zolfaghari MR, Mohammadbeigi A. The Prevalence of Hepatitis B and D Viruses and Evaluating YMDD Mutation in HBV-Suspected Patients in Qom Province, Iran. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.100038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020; 26(9): 883-903 [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
108 Alawad AS, Auh S, Suarez D, Ghany MG. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clin Gastroenterol Hepatol 2020;18:700-709.e3. [PMID: 31323381 DOI: 10.1016/j.cgh.2019.07.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
109 Younesi S, Parsian H. Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: A comparison between laminin, fibronectin, and hyaluronic acid. Turk J Gastroenterol 2019;30:524-31. [PMID: 31144658 DOI: 10.5152/tjg.2019.17339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
110 Guo Y, Lu H, Xu L, Idris NFB, Li Y, Hu J, Huang A, Tu Z. The response of hepatitis B virus genotype to interferon is associated with a mutation in the interferon-stimulated response element. Medicine (Baltimore). 2019;98:e18442. [PMID: 31861015 DOI: 10.1097/md.0000000000018442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 El-kamary SS, Kottilil S. Viral Hepatitis. Hunter's Tropical Medicine and Emerging Infectious Diseases 2020. [DOI: 10.1016/b978-0-323-55512-8.00035-1] [Reference Citation Analysis]
112 Fong IW. Major Advances in Hepatitis C Treatment but Not Hepatitis B. Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_5] [Reference Citation Analysis]
113 Dienes HP, Drebber U. Akute und chronische Hepatitis. Pathologie 2020. [DOI: 10.1007/978-3-642-04557-8_7] [Reference Citation Analysis]
114 Pryce DJ. Viral Hepatitis. Refugee Health Care 2020. [DOI: 10.1007/978-3-030-47668-7_7] [Reference Citation Analysis]
115 Tao S, Pan S, Gu C, Wei L, Kang N, Xie Y, Liu J. Characterization and engineering of broadly reactive monoclonal antibody against hepatitis B virus X protein that blocks its interaction with DDB1. Sci Rep 2019;9:20323. [PMID: 31889135 DOI: 10.1038/s41598-019-56819-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Zeng Y, Luo M, Lin J, He H, Deng X, Xie S, Fang Y. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China. Hum Vaccin Immunother 2020;16:955-64. [PMID: 31769718 DOI: 10.1080/21645515.2019.1688031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Zyoud SH. Global scientific trends on aflatoxin research during 1998-2017: a bibliometric and visualized study. J Occup Med Toxicol. 2019;14:27. [PMID: 31832075 DOI: 10.1186/s12995-019-0248-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
118 Davies J, Smith EL, Littlejohn M, Edwards R, Sozzi V, Jackson K, Mcguire K, Binks P, Cowie BC, Locarnini S, Davis JS, Tong SYC. Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. Open Forum Infect Dis 2019;6:ofz469. [PMID: 32864387 DOI: 10.1093/ofid/ofz469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
119 Ommen CV, Albert A, Nourmoussavi M, Gustafson R, Brodkin E, Petric M, Krajden M, Buxton JA, Bigham M, Pick N, Schreiber RA, Sherlock CH, Money D, Yoshida EM, Schalkwyk JV. Stability of hepatitis B viral load during pregnancy and implications for antepartum prophylaxis: A prospective cohort study. CanLivJ 2019;2:190-8. [DOI: 10.3138/canlivj.2019-0001] [Reference Citation Analysis]
120 Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One 2019;14:e0222196. [PMID: 31639131 DOI: 10.1371/journal.pone.0222196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
121 Oliveira MS, Silva RPM, Valle SDCND, Souza RM, Figueiredo EN, Taminato M, Fram DS. Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia. Rev Bras Enferm 2019;72:1265-70. [PMID: 31531650 DOI: 10.1590/0034-7167-2018-0100] [Reference Citation Analysis]
122 Nandi M, Pal S, Ghosh S, Chakraborty BC, Dey D, Baidya A, Shil A, Chattopadhyaya S, Banerjee S, Santra A, Chowdhury A, Datta S. CD8+CD28- T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection. Clin Sci (Lond) 2019;133:1917-34. [PMID: 31477625 DOI: 10.1042/CS20190369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
124 Babanejad M, Izadi N, Alavian SM. A Systematic Review and Meta-analysis on the Prevalence of HBsAg in Health Care Workers from Eastern Mediterranean and Middle Eastern Countries.Int J Prev Med. 2019;10:144. [PMID: 31516685 DOI: 10.4103/ijpvm.IJPVM_111_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
126 Guo Y, Gao P, Wang H, Wu J, Bai Q, Huang L, Li S, Lv M, Shi X. Risk factors of hepatitis B virus infection between vaccinated and unvaccinated groups among spouses in 2006 and 2014: a cross-sectional study in Beijing. Hum Vaccin Immunother 2020;16:148-57. [PMID: 31287778 DOI: 10.1080/21645515.2019.1640428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
127 Mahmoudian-Sani MR, Asgharzade S, Alghasi A, Saeedi-Boroujeni A, Adnani Sadati SJ, Moradi MT. MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol 2019;10:789-96. [PMID: 31392060 DOI: 10.21037/jgo.2019.02.14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
128 Su KJ, Yu YL. Downregulation of SHIP2 by Hepatitis B Virus X Promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2. Cancers (Basel) 2019;11:E1065. [PMID: 31357665 DOI: 10.3390/cancers11081065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
129 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
130 Bridges CB, Watson TL, Nelson NP, Chavez-Torres M, Fineis P, Ntiri-Reid B, Wake E, Leahy JM, Kurian AK, Hall MAK, Kennedy ED. Challenges with hepatitis B vaccination of high risk adults - A pilot program. Vaccine 2019;37:5111-20. [PMID: 31303523 DOI: 10.1016/j.vaccine.2019.05.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
131 Thomas E, Baumert TF. Hepatitis B Virus-Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms. Semin Liver Dis 2019;39:301-14. [PMID: 31266064 DOI: 10.1055/s-0039-1685518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
132 Raihan R, Akbar SMF, Al Mahtab M, Takahashi K, Masumoto J, Tabassum S, Tee KK, Binti Mohamed R. Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh. PLoS One 2019;14:e0218744. [PMID: 31251754 DOI: 10.1371/journal.pone.0218744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
134 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
135 Wang W, Dong R, Guo Y, He J, Shao C, Yi P, Yu F, Gu D, Zheng J. CircMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7. J Cell Mol Med 2019;23:5486-96. [PMID: 31148365 DOI: 10.1111/jcmm.14432] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
136 Kakisaka K, Sakai A, Yoshida Y, Miyasaka A, Takahashi F, Sumazaki R, Takikawa Y. Hepatitis B Surface Antibody Titers at One and Two Years after Hepatitis B Virus Vaccination in Healthy Young Japanese Adults. Intern Med 2019;58:2349-55. [PMID: 31118375 DOI: 10.2169/internalmedicine.2231-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
137 Al-Anazi MR, Matou-Nasri S, Al-Qahtani AA, Alghamdi J, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Shamsi MB, Alanazi SK, Dela Cruz D, Bohol MFF, Al-Ahdal MN, Al-Qahtani AA. Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population. Sci Rep 2019;9:7123. [PMID: 31073186 DOI: 10.1038/s41598-019-42808-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
138 Pal S, Nandi M, Dey D, Chakraborty BC, Shil A, Ghosh S, Banerjee S, Santra A, Ahammed SKM, Chowdhury A, Datta S. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther 2019;49:1346-59. [PMID: 30982998 DOI: 10.1111/apt.15226] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
139 Ji J, Zhang Y, Fan Y. TIPE2 as a potential therapeutic target in chronic viral hepatitis. Expert Opinion on Therapeutic Targets 2019;23:485-93. [DOI: 10.1080/14728222.2019.1608948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
140 Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, Holdorf MM. Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients. J Virol 2019;93:e02036-18. [PMID: 30787147 DOI: 10.1128/JVI.02036-18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
141 Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-476. [PMID: 30982722 DOI: 10.1016/s2468-1253(19)30042-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 16.5] [Reference Citation Analysis]
142 Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, Espinosa N, Viciana P, López-Cortés LF. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine 2019;37:2758-63. [PMID: 30981625 DOI: 10.1016/j.vaccine.2019.03.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
143 Matlou MK, Gaelejwe LR, Musyoki AM, Rakgole JN, Selabe SG, Amponsah-Dacosta E. A novel hepatitis B virus recombinant genotype D4/E identified in a South African population. Heliyon 2019;5:e01477. [PMID: 31008405 DOI: 10.1016/j.heliyon.2019.e01477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
144 Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-9. [PMID: 30922728 DOI: 10.1016/j.clinre.2019.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
145 Xu J, Xia Y, Li S, Cheng X, Hu S, Gao Y, Zhou X, Wang G, Zheng Q. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Ann Clin Biochem 2019;56:357-66. [PMID: 30453754 DOI: 10.1177/0004563218817797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
146 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
147 Xu L, Hu C, Hu H, Dai X, Gao H, Guo Y, Huang Y, Yang Z, Tao R, Zhu B, Xu Y. Importance of fibrosis 4 index score and mode of anti-fungal treatment to the outcome of Cryptococcal meningitis in hepatitis B virus-infected patients. Infect Dis (Lond) 2019;51:113-21. [PMID: 30676149 DOI: 10.1080/23744235.2018.1523553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
148 Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol 2019;4:227-38. [PMID: 30679109 DOI: 10.1016/S2468-1253(18)30308-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
149 Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, Soltanzadeh-Yamchi M, Mohammadnia-Afrouzi M. TIM-3 as a marker of exhaustion in CD8+ T cells of active chronic hepatitis B patients. Microb Pathog 2019;128:323-8. [PMID: 30660734 DOI: 10.1016/j.micpath.2019.01.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
150 Hong M, Bertoletti A. Immune Tolerance and Hepatitis B. Viral Hepatitis in Children 2019. [DOI: 10.1007/978-981-13-0050-9_8] [Reference Citation Analysis]
151 Johnson P. The Epidemiology of Hepatocellular Carcinoma. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_1] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Fotos NV, Elefsiniotis I, Patelarou A, Giakoumidakis K, Patelarou E, Kouros A, Brokalaki H. Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. Gastroenterol Nurs 2018;41:206-18. [PMID: 29847395 DOI: 10.1097/SGA.0000000000000339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
153 Ahmed Z, Ren J, Gonzalez A, Ahmed U, Walayat S, Martin DK, Moole H, Yong S, Koppe S, Dhillon S. Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease. Hepat Med 2018;10:133-8. [PMID: 30498378 DOI: 10.2147/HMER.S160616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
154 Biswas R, Golabi P, Younossi ZM. Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes. Curr Hepatology Rep 2018;17:459-465. [DOI: 10.1007/s11901-018-0434-6] [Reference Citation Analysis]
155 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
156 Fletcher GJ, Anantharam R, Radhakrishnan K, Singh U, Karunakaran A, Jeyaseelan V, Abraham P. Evaluation of reliability and performance of hepatitis B virus-e-antigen assays in tertiary care setting. J Immunoassay Immunochem 2018;39:622-35. [PMID: 30362912 DOI: 10.1080/15321819.2018.1529680] [Reference Citation Analysis]
157 Li H, Zhai N, Wang Z, Song H, Yang Y, Cui A, Li T, Wang G, Niu J, Crispe IN, Su L, Tu Z. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut 2018;67:2035-44. [PMID: 28899983 DOI: 10.1136/gutjnl-2017-314098] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 13.6] [Reference Citation Analysis]
158 Zhou TC, Li X, Chen LJ, Fan JH, Lai X, Tang Y, Zhang L, Wei J. Differential expression profile of hepatic circular RNAs in chronic hepatitis B. J Viral Hepat 2018;25:1341-51. [PMID: 29888838 DOI: 10.1111/jvh.12944] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
159 Wang M, Liu X, Lin S, Tian T, Guan F, Guo Y, Li X, Deng Y, Zheng Y, Xu P, Hao Q, Zhai Z, Dai Z. FABP1 Polymorphisms Contribute to Hepatocellular Carcinoma Susceptibility in Chinese Population with Liver Cirrhosis: A Case-Control Study. J Cancer 2018;9:4294-300. [PMID: 30519332 DOI: 10.7150/jca.27301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
160 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol 2018; 10(9): 558-570 [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
161 Çelik M, Vatansever S, Kandemir A, Ünsal B. KRONİK HEPATİT B ENFEKSİYONUNUNDA HEPATİK HASAR DÜZEYİNİN ÖNGÖRÜLMESİNDE M30 VE M65 ANTİJEN DÜZEYLERİNİN ETKİNLİĞİ. Akademik Gastroenteroloji Dergisi 2018. [DOI: 10.17941/agd.456947] [Reference Citation Analysis]
162 Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther 2018;18:1085-94. [PMID: 30182763 DOI: 10.1080/14712598.2018.1518423] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
163 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
164 Xing YF, Zhou DQ, He JS, Wei CS, Zhong WC, Han ZY, Peng DT, Shao MM, Sham TT, Mok DK, Chan CO, Tong GD. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China. PLoS One. 2018;13:e0203220. [PMID: 30180183 DOI: 10.1371/journal.pone.0203220] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
165 Akcay IM, Katrinli S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol 2018; 24(30): 3347-3360 [PMID: 30122875 DOI: 10.3748/wjg.v24.i30.3347] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
166 Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900-9. [PMID: 29132759 DOI: 10.1016/S2468-1253(17)30295-9] [Cited by in Crossref: 139] [Cited by in F6Publishing: 150] [Article Influence: 27.8] [Reference Citation Analysis]
167 Kodali S, Singal AK. Potent suppression of hepatitis B virus and hepatocellular carcinoma: how long is good enough? Hepatobiliary Surg Nutr 2018;7:212-3. [PMID: 30046577 DOI: 10.21037/hbsn.2018.03.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
168 Wang W, Tong Z, Zhong J, Zhang L, Zhang H, Su Y, Gao B, Zhang C. Identification of IL-10-secreting CD8+CD28-PD-1+ regulatory T cells associated with chronic hepatitis C virus infection. Immunol Lett 2018;202:16-22. [PMID: 30055200 DOI: 10.1016/j.imlet.2018.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
169 Chen T, Wang J, Qiu H, Yu Q, Yan T, Qi C, Cao F, Tian Z, Guo D, Yao N, Yang Y, He Y, Zhao Y, Liu J. Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. Medicine (Baltimore) 2018;97:e11406. [PMID: 29979437 DOI: 10.1097/MD.0000000000011406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
170 Choe WH, Kim H, Lee SY, Choi YM, Kwon SY, Moon HW, Hur M, Kim BJ. Three types of preS1 start codon deletion variants in the natural course of chronic hepatitis B infection. J Gastroenterol Hepatol 2018;33:1370-8. [PMID: 29232004 DOI: 10.1111/jgh.14069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
171 Lal BB, Sood V, Khanna R, Rawat D, Verma S, Alam S. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children. Indian J Gastroenterol 2018;37:326-34. [PMID: 30168073 DOI: 10.1007/s12664-018-0878-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
172 Goyal A, Chauhan R. The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection. J Theor Biol 2018;455:269-80. [PMID: 29969598 DOI: 10.1016/j.jtbi.2018.06.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
173 Coppola N, Onorato L, Panella M, de Stefano G, Mosca N, Minichini C, Messina V, Potenza N, Starace M, Alessio L, Farella N, Sagnelli E, Russo A. Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection. Front Immunol 2018;9:1334. [PMID: 29951066 DOI: 10.3389/fimmu.2018.01334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
174 Harris AM, Link-Gelles R, Kim K, Chandrasekar E, Wang S, Bannister N, Pong P, Chak E, Chen MS Jr, Bowlus C, Nelson NP. Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017. MMWR Morb Mortal Wkly Rep 2018;67:541-6. [PMID: 29771873 DOI: 10.15585/mmwr.mm6719a2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
175 Wang Y, Liang X, Yang J, Wang H, Tan D, Chen S, Cheng J, Chen Y, Sun J, Rong F, Yang W, Liu H, Liu Z, Zheng Y, Liang J, Li S, Liu Z, Hou J. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat 2018;25:598-607. [PMID: 29193542 DOI: 10.1111/jvh.12835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
176 Hou X, Ye F, Li X, Liu W, Jing Y, Han Z, Wei L. Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis. Cellular Immunology 2018;326:52-9. [DOI: 10.1016/j.cellimm.2017.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
177 Siyahian A, Malik SU, Mushtaq A, Howe CL, Majeed A, Zangeneh T, Iftikhar S, Habib S, Zahid U, Riaz IB, Warraich Z, Faridi W, Anwer F. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:1483-9. [PMID: 29545185 DOI: 10.1016/j.bbmt.2018.02.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
178 Li XY, You X, Jie YS, Lin GL, Wu YK, Huang MX, Zhang M, Li ZY, Xie DY, Gao ZL, Chong YT. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy. Am J Ther 2017;24:e250-8. [PMID: 25923228 DOI: 10.1097/MJT.0000000000000262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Lee KJ, Choe BH, Choe JY, Kim JY, Jeong IS, Kim JW, Yang HR, Chang JY, Kim KM, Moon JS, Ko JS. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B. J Korean Med Sci 2018;33:e63. [PMID: 29441755 DOI: 10.3346/jkms.2018.33.e63] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
180 Lee D, Shin HY, Park SM. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Eff Resour Alloc 2018;16:6. [PMID: 29467596 DOI: 10.1186/s12962-018-0088-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
181 Zhou K, Terrault N. Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy? AME Med J 2018;3:27. [PMID: 31058256 DOI: 10.21037/amj.2018.02.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
182 Kim H, Chung YK, Kim I. Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea. Ann Occup Environ Med 2018;30:6. [PMID: 29423229 DOI: 10.1186/s40557-018-0217-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
183 Li J, Zhang TY, Song LW, Qi X, Yu XP, Li FH, Zhou P, Qin YL, Yang L, Zhao JH, Mao RC, Zhang YM, Wang JY, Yang FF, Zhu HX, Yang SS, Huang YX, Yuan Q, Zhang J, Zhang JM, Xia NS. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol Res 2018;48:E133-45. [PMID: 28707778 DOI: 10.1111/hepr.12937] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
184 Doi H, Morikawa K, Kanto T. Immunity against Hepatitis B Virus and HBV Vaccines. eLS 2018. [DOI: 10.1002/9780470015902.a0026254] [Reference Citation Analysis]
185 Liu H, Li F, Zhang X, Yu J, Wang J, Jia J, Yu X, Shen Z, Yuan Z, Zhang X, Zhang Z, Zhang X, Lu L, Li H, Lu M, Zhang J. Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. The Journal of Infectious Diseases 2018;217:1044-54. [DOI: 10.1093/infdis/jix683] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
186 Elizalde MM, Sevic I, González López Ledesma MM, Campos RH, Barbini L, Flichman DM. Human hepatocytes apoptosis induced by replication of hepatitis B virus subgenotypes F1b and F4: Role of basal core promoter and preCore mutations. Virology 2018;513:160-7. [DOI: 10.1016/j.virol.2017.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
187 Collier MG, Schillie S. Hepatitis B and Hepatitis D Viruses. Principles and Practice of Pediatric Infectious Diseases 2018. [DOI: 10.1016/b978-0-323-40181-4.00213-9] [Reference Citation Analysis]
188 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines 2018. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
189 Zacharakis G. Hepatitis B and C Coinfection. Hepatitis C in Developing Countries 2018. [DOI: 10.1016/b978-0-12-803233-6.00013-8] [Reference Citation Analysis]
190 Yang H. Viral Factors Affecting Disease Progression. Hepatitis B Virus and Liver Disease 2018. [DOI: 10.1007/978-981-10-4843-2_6] [Reference Citation Analysis]
191 Shen Z, Yang H, Yang S, Wang W, Cui X, Zhou X, Liu W, Pan S, Liu Y, Zhang J, Zhang J, Xie Y, Liu J. Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance. Nat Commun 2017;8:2119. [PMID: 29242561 DOI: 10.1038/s41467-017-02304-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
192 Goyal A, Ribeiro RM, Perelson AS. The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses 2017;9:E350. [PMID: 29156567 DOI: 10.3390/v9110350] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
193 Amponsah-Dacosta E, Selabe SG, Mphahlele MJ. Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients. J Med Virol 2018;90:291-303. [PMID: 28971485 DOI: 10.1002/jmv.24956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
194 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 151] [Cited by in F6Publishing: 154] [Article Influence: 25.2] [Reference Citation Analysis]
195 Hu CC, Jeng WJ, Chen YC, Fang JH, Huang CH, Teng W, Hsieh YC, Lin YC, Chien RN, Sheen IS, Lin CY. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. Sci Rep 2017;7:15280. [PMID: 29127350 DOI: 10.1038/s41598-017-15527-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
196 Arends JE, Lieveld FI, Ahmad S, Ustianowski A. New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. Infect Dis Ther 2017;6:461-76. [PMID: 29071665 DOI: 10.1007/s40121-017-0173-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
197 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
198 Zhou X, Wang L, Wang G, Cheng X, Hu S, Ke W, Li M, Zhang Y, Song Z, Zheng Q. A new plasma biomarker enhance the clinical prediction of postoperative acute kidney injury in patients with hepatocellular carcinoma. Clin Chim Acta 2017;475:128-36. [PMID: 29031454 DOI: 10.1016/j.cca.2017.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
199 Li W, Shen X, Fu B, Guo C, Liu Y, Ye Y, Sun R, Li J, Tian Z, Wei H. KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B. Front Immunol 2017;8:1285. [PMID: 29075265 DOI: 10.3389/fimmu.2017.01285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
200 Zhan W, Kang Y, Chen N, Mao C, Kang Y, Shang J. Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation. Drug Des Devel Ther 2017;11:2947-55. [PMID: 29066866 DOI: 10.2147/DDDT.S149623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
201 Shedain PR, Devkota MD, Banjara MR, Ling H, Dhital S. Prevalence and risk factors of hepatitis B infection among mothers and children with hepatitis B infected mother in upper Dolpa, Nepal. BMC Infect Dis 2017;17:667. [PMID: 29017456 DOI: 10.1186/s12879-017-2763-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
202 Li M, Chen L, Liu LM, Li YL, Li BA, Li B, Mao YL, Xia LF, Wang T, Liu YN, Li Z, Guo TS. Performance verification and comparison of TianLong automatic hypersensitive hepatitis B virus DNA quantification system with Roche CAP/CTM system. World J Gastroenterol 2017; 23(37): 6845-6853 [PMID: 29085227 DOI: 10.3748/wjg.v23.i37.6845] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Baldassarre A, Felli C, Prantera G, Masotti A. Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases. Genes (Basel) 2017;8:E234. [PMID: 28925938 DOI: 10.3390/genes8090234] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
204 Wang M, Wang Y, Feng X, Wang R, Zeng H, Qi J, Zhao H, Li N, Cai J, Qu C. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis. 2017;65:15-21. [PMID: 28935244 DOI: 10.1016/j.ijid.2017.09.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
205 Adenlewo OJ, Adeosun PO, Fatusi OA. Medical and dental students' attitude and practice of prevention strategies against hepatitis B virus infection in a Nigerian university. Pan Afr Med J 2017;28:33. [PMID: 29138669 DOI: 10.11604/pamj.2017.28.33.11662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
206 Ortega-Prieto AM, Dorner M. Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel). 2017;5:pii: E24. [PMID: 28862649 DOI: 10.3390/vaccines5030024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
207 Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
208 Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Viral Hepat 2017;24:776-88. [PMID: 28218976 DOI: 10.1111/jvh.12699] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
209 Komijani M, Kardi MT, Shahin K, Yazdi M, Department of Biology, Faculty of Science, Arak University, Arak, Iran, Department of Microbiology, Mahdieh Laboratory, Isfahan, Iran, State Key Laboratory Cultivation Base of Most, Institute of Food Safety and Nutrition, Jiangusa Academy of Agricultural Sciences, Nanjing 210014,PR China, Department of Biology, Faculty of Sciences, University of Isfahan, 81746073441 Isfahan, IR Iran. Detection of Mediterranean Hepatitis B in a 45 Years Old Man in Mahdieh Clinical Laboratory, Isfahan, Iran. mljgoums 2017;11:33-35. [DOI: 10.29252/mlj.11.5.33] [Reference Citation Analysis]
210 Boyle M, Mann J. WITHDRAWN: Epigenetics in Chronic Liver Disease. J Hepatol 2017:S0168-8278(17)32255-9. [PMID: 28855099 DOI: 10.1016/j.jhep.2017.08.016] [Reference Citation Analysis]
211 Li X, Heffelfinger J, Wiesen E, Diorditsa S, Valiakolleri J, Nikuata AB, Nukuro E, Tabwaia B, Woodring J. Improving hepatitis B birth dose coverage through village health volunteer training and pregnant women education. Vaccine 2017;35:4396-401. [DOI: 10.1016/j.vaccine.2017.06.056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
212 Li MR, Zheng HW, Lu JH, Ma SM, Ye LH, Liu ZQ, Zhang HC, Liu YY, Lv Y, Huang Y, Dai EH, Sun DX. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B. Oncotarget 2017;8:11063-70. [PMID: 28052021 DOI: 10.18632/oncotarget.14323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
213 Hösel M, Quasdorff M, Ringelhan M, Kashkar H, Debey-Pascher S, Sprinzl MF, Bockmann JH, Arzberger S, Webb D, von Olshausen G, Weber A, Schultze JL, Büning H, Heikenwalder M, Protzer U. Hepatitis B Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and Virus Replication. Cell Mol Gastroenterol Hepatol 2017;4:339-63. [PMID: 28884137 DOI: 10.1016/j.jcmgh.2017.07.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
214 Wu HJ, Zhuo Y, Zhou YC, Wang XW, Wang YP, Si CY, Wang XH. miR-29a promotes hepatitis B virus replication and expression by targeting SMARCE1 in hepatoma carcinoma. World J Gastroenterol 2017; 23(25): 4569-4578 [PMID: 28740345 DOI: 10.3748/wjg.v23.i25.4569] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
215 Yu F, Zhou G, Huang K, Fan X, Li G, Chen B, Dong P, Zheng J. Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients. J Viral Hepat 2017;24:580-8. [PMID: 28107589 DOI: 10.1111/jvh.12680] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
216 Wei X, Wei H, Lin W, Hu Z, Zhang J. Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B: A cross-sectional study of diagnostic accuracy. Medicine (Baltimore) 2017;96:e6807. [PMID: 28514295 DOI: 10.1097/MD.0000000000006807] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
217 Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Current Opinion in Virology 2017;24:38-45. [DOI: 10.1016/j.coviro.2017.03.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
218 Chen Y, Fan C, Chen Y, Liu H, Wang S, Dong P, Li L, Ding H. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study. Oncotarget 2017;8:58601-10. [PMID: 28938582 DOI: 10.18632/oncotarget.17380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
219 Katrinli S, Ozdil K, Sahin A, Ozturk O, Kir G, Baykal AT, Akgun E, Sarac OS, Sokmen M, Doğanay HL, Dinler Doğanay G. Proteomic profiling of HBV infected liver biopsies with different fibrotic stages. Proteome Sci 2016;15:7. [PMID: 28439208 DOI: 10.1186/s12953-017-0114-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
220 Fan CX, Li XF, Zhan YF, Zheng QY, Feng Q, Shi XY, Li YJ, Tan HB. Efficacy and safety of interferon α-2b as an add-on therapy to long-term oral nucleotide analogue therapy in hepatitis B e antigen-negative patients. Shijie Huaren Xiaohua Zazhi 2017; 25(11): 983-988 [DOI: 10.11569/wcjd.v25.i11.983] [Reference Citation Analysis]
221 Yang J, Yan D, Guo R, Chen J, Li Y, Fan J, Fu X, Yao X, Diao H, Li L. Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment. Medicine (Baltimore). 2017;96:e6242. [PMID: 28272219 DOI: 10.1097/md.0000000000006242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
222 Liu C, Huang X, Werner M, Broering R, Ge J, Li Y, Liao B, Sun J, Peng J, Lu M, Hou J, Zhang X. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol 2017;8:323. [PMID: 28386259 DOI: 10.3389/fimmu.2017.00323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
223 Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: Opportunities for Early Cancer Detection. Trends Cancer. 2017;3:198-213. [PMID: 28718432 DOI: 10.1016/j.trecan.2017.02.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 11.5] [Reference Citation Analysis]
224 Castillo E, Murphy K, van Schalkwyk J. N° 342-L'hépatite B et la grossesse. Journal of Obstetrics and Gynaecology Canada 2017;39:191-201. [DOI: 10.1016/j.jogc.2017.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Castillo E, Murphy K, van Schalkwyk J. No. 342-Hepatitis B and Pregnancy. Journal of Obstetrics and Gynaecology Canada 2017;39:181-90. [DOI: 10.1016/j.jogc.2016.11.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
226 Huang S, Xia Y, Lei Z, Zou Q, Li J, Yang T, Wang K, Yan Z, Wan X, Shen F. Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. Journal of the American College of Surgeons 2017;224:283-293.e4. [DOI: 10.1016/j.jamcollsurg.2016.11.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
227 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) 2016;95:e4832. [PMID: 27603400 DOI: 10.1097/MD.0000000000004832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
228 Zou ZQ, Zhang S, Lin Q, Qu RL, Li YF, Zhang FH, Xu AL. Immune response- and viral control-related pathways in the progression of chronic hepatitis B. Microb Pathog 2017;105:100-5. [PMID: 28189731 DOI: 10.1016/j.micpath.2017.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
229 Chen F, Zhang J, Guo F, Wen B, Luo S, Yuan D, Lin Y, Ou W, Tang P, Dai G, Li F, Liu W, Qu X. Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users and the general population. J Gastroenterol Hepatol 2017;32:515-20. [PMID: 27248508 DOI: 10.1111/jgh.13460] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
230 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 7.7] [Reference Citation Analysis]
231 Enomoto H, Aizawa N, Nishikawa H, Ikeda N, Sakai Y, Takata R, Hasegawa K, Nakano C, Nishimura T, Yoh K, Ishii A, Takashima T, Iwata Y, Iijima H, Nishiguchi S. Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load. Medicine (Baltimore) 2016;95:e3565. [PMID: 27124068 DOI: 10.1097/MD.0000000000003565] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
232 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8:152-161. [PMID: 28243319 DOI: 10.7150/jca.16523] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
233 Ryu W. Hepatitis Viruses. Molecular Virology of Human Pathogenic Viruses 2017. [DOI: 10.1016/b978-0-12-800838-6.00023-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
234 Roll GR, Roberts JP. Liver transplantation for hepatocellular carcinoma. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00115-1] [Reference Citation Analysis]
235 Spearman CW, de Lacy R, Goddard E. Viral Hepatitis. Viral Infections in Children, Volume II 2017. [DOI: 10.1007/978-3-319-54093-1_7] [Reference Citation Analysis]
236 Hepatitis B. Diagnostic Pathology: Hepatobiliary and Pancreas 2017. [DOI: 10.1016/b978-0-323-44307-4.50026-9] [Reference Citation Analysis]
237 Lee J, Shin J, Park Y, Kim D. Mitochondrial myopathies caused by prolonged use of telbivudine. Ann Clin Neurophysiol 2017;19:40. [DOI: 10.14253/acn.2017.19.1.40] [Reference Citation Analysis]
238 Bao S, Zheng J, Li N, Huang C, Chen M, Cheng Q, Li Q, Lu Q, Zhu M, Ling Q, Yu K, Chen S, Shi G. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage. Clin Res Hepatol Gastroenterol. 2017;41:147-155. [PMID: 28041935 DOI: 10.1016/j.clinre.2016.10.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
239 Ferreira SD, Chachá SG, Souza FF, Teixeira AC, Santana RC, Deghaide NH, Rodrigues S, Marano LA, Mendes-Junior CT, Ramalho LN, Zucoloto S, Donadi EA, Martinelli AL. The HLA-G 14-base pair deletion allele and the deletion/deletion genotype are associated with persistent HBe antigenemia in chronic hepatis B infection. Hum Immunol 2017;78:166-71. [PMID: 28041834 DOI: 10.1016/j.humimm.2016.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
240 Chen C, Zhang SY, Zhang DD, Li XY, Zhang YL, Li WX, Yan JJ, Wang M, Xun JN, Lu C, Ling Y, Huang YX, Chen L. Clinical features of acute hepatitis E super-infections on chronic hepatitis B. World J Gastroenterol 2016; 22(47): 10388-10397 [PMID: 28058019 DOI: 10.3748/wjg.v22.i47.10388] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
241 Babanejad M, Izadi N, Rai A, Sohrabzadeh S, Alavian SM, Zangeneh A. Prevalence of HBsAg Amongst Healthy Children in Eastern Mediterranean and Middle Eastern Countries: A Systematic Review and Meta-Analysis. Iran Red Crescent Med J 2016;19. [DOI: 10.5812/ircmj.41507] [Reference Citation Analysis]
242 Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, Cowie B, Hall WD, Strang J, Whiteford H, Vos T. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:1385-98. [PMID: 27665254 DOI: 10.1016/S1473-3099(16)30325-5] [Cited by in Crossref: 171] [Cited by in F6Publishing: 176] [Article Influence: 24.4] [Reference Citation Analysis]
243 Zhang Q, Deng YL, Liu C, Huang LH, Shang L, Chen XG, Wang LT, Du JZ, Wang Y, Wang PX, Zhang H, Shen ZY. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2016; 22(43): 9571-9585 [PMID: 27920478 DOI: 10.3748/wjg.v22.i43.9571] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
244 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Teshale ET, Lu M, Boscarino JA, Schmidt MA, Trinacty CM, Holmberg SD; Chronic Hepatitis Cohort Study Investigators. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013. Aliment Pharmacol Ther 2016;44:1080-9. [PMID: 27640985 DOI: 10.1111/apt.13802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
245 Cai QC, Zhao SQ, Shi TD, Ren H. Relationship between hepatitis B virus infection and chronic kidney disease in Asian populations: a meta-analysis. Ren Fail 2016;38:1581-8. [PMID: 27756165 DOI: 10.1080/0886022X.2016.1229548] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
246 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 583] [Cited by in F6Publishing: 643] [Article Influence: 83.3] [Reference Citation Analysis]
247 Pawłowska M, Domagalski K, Smok B, Rajewski P, Wietlicka-Piszcz M, Halota W, Tretyn A. Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents - A Longitudinal Study in Real Life. PLoS One 2016;11:e0163691. [PMID: 27685782 DOI: 10.1371/journal.pone.0163691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
248 Angounda BM, Ngouloubi GH, Dzia AB, Boumba LMA, Baha W, Moukassa D, Ahombo G, Ennaji MM, Ibara JR. Molecular characterization of hepatitis B virus among chronic hepatitis B patients from Pointe Noire, Republic of Congo. Infect Agent Cancer 2016;11:51. [PMID: 27651827 DOI: 10.1186/s13027-016-0088-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
249 Rafia R, Dodd PJ, Brennan A, Meier PS, Hope VD, Ncube F, Byford S, Tie H, Metrebian N, Hellier J, Weaver T, Strang J. An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction 2016;111:1616-27. [PMID: 26990598 DOI: 10.1111/add.13385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
250 Sung FY, Lan CY, Huang CJ, Lin CL, Liu CJ, Chen PJ, Lin SM, Yu MW. Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. Hepatology 2016;64:720-31. [PMID: 27228506 DOI: 10.1002/hep.28654] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
251 Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) 2016;95:e3328. [PMID: 27057911 DOI: 10.1097/MD.0000000000003328] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
252 Shiferaw F, Letebo M, Bane A. Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia. BMC Public Health 2016;16:769. [PMID: 27514515 DOI: 10.1186/s12889-016-3459-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
253 Baudi I, Iijima S, Chin'ombe N, Mtapuri-Zinyowera S, Murakami S, Isogawa M, Hachiya A, Iwatani Y, Tanaka Y. Molecular epidemiology of co-infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe. J Med Virol 2017;89:257-66. [PMID: 27458715 DOI: 10.1002/jmv.24641] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
254 Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J, Chen D, Su X, Li L. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016;6:30853. [PMID: 27498553 DOI: 10.1038/srep30853] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
255 Chen Y, Xu Y, Zhao M, Liu Y, Gong M, Xie C, Wu H, Wang Z. High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. Oncoimmunology 2016;5:e1219010. [PMID: 27853640 DOI: 10.1080/2162402X.2016.1219010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
256 McMahon BJ. Editorial Commentary: Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection. Clin Infect Dis 2016;63:1209-11. [PMID: 27486113 DOI: 10.1093/cid/ciw517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
257 Stawinska-Witoszynska B, Zysnarska M, Krzywinska-Wiewiorowska M, Wojtyła-Buciorab P, Krzyzaniak A, Wieckowska B. Trends in the Incidence Rates of Chronic Hepatitis B in Poland in the Years 2005 - 2013. Hepat Mon 2016;16:e32692. [PMID: 27799960 DOI: 10.5812/hepatmon.32692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
258 Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol 2016; 22(27): 6201-6213 [PMID: 27468210 DOI: 10.3748/wjg.v22.i27.6201] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
259 Lizaola B, Bonder A, Tapper EB, Afdhal N. Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. Curr Hepatology Rep 2016;15:220-9. [DOI: 10.1007/s11901-016-0311-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Li H, Song XF, Hu TT, Ren H, Hu P. A strong conservative tendency in HBV transcriptase (RT): a majority of natural RT mutations derived from the S gene. Liver Int 2016;36:963-70. [PMID: 26707356 DOI: 10.1111/liv.13051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
261 Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Kamimura K, Yano M. Natural regression of fibrosis in chronic hepatitis B. World J Gastroenterol 2016; 22(24): 5459-5466 [PMID: 27350724 DOI: 10.3748/wjg.v22.i24.5459] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
262 Yang Y, Han Q, Zhang C, Xiao M, Zhang J. Hepatitis B virus antigens impair NK cell function. Int Immunopharmacol. 2016;38:291-297. [PMID: 27341035 DOI: 10.1016/j.intimp.2016.06.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
263 Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int 2016;10:924-36. [PMID: 27271357 DOI: 10.1007/s12072-016-9741-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
264 Yuan L, Wang T, Zhang Y, Liu X, Zhang T, Li X, Liu P, Wu K, Shih JW, Yuan Q, Cheng T, Xia N. An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. Exp Anim 2016;65:373-82. [PMID: 27264142 DOI: 10.1538/expanim.16-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
265 Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board. Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?". Hum Vaccin Immunother 2016;12:2053-6. [PMID: 27261211 DOI: 10.1080/21645515.2016.1177689] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
266 Zhang XX, Li MR, Cao Y, Zhang RW, Zhang Y, Li F, Xi HL, Xu XY. Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study. Medicine (Baltimore) 2016;95:e2614. [PMID: 26825915 DOI: 10.1097/MD.0000000000002614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
267 Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017;14:465-475. [PMID: 27238466 DOI: 10.1038/cmi.2016.24] [Cited by in Crossref: 115] [Cited by in F6Publishing: 127] [Article Influence: 16.4] [Reference Citation Analysis]
268 Yang H, Kao J. Revisiting the Natural History of Chronic HBV Infection. Curr Hepatology Rep 2016;15:141-9. [DOI: 10.1007/s11901-016-0304-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
269 Sun YY, Fan YC, Wang N, Xia HH, Xiao XY, Wang K. Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. Medicine (Baltimore) 2015;94:e2428. [PMID: 26717404 DOI: 10.1097/MD.0000000000002428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
270 Zeybel M, Vatansever S, Hardy T, Sarı AA, Cakalağaoğlu F, Avcı A, Zeybel GL, Karahüseyinoğlu S, Bashton M, Mathers JC, Ünsal B, Mann J. DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease. Clin Epigenetics 2016;8:48. [PMID: 27152124 DOI: 10.1186/s13148-016-0218-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
271 Zhang X, Liu H, Xie Z, Deng W, Wu C, Qin B, Hou J, Lu M. Epigenetically regulated miR-449a enhances hepatitis B virus replication by targeting cAMP-responsive element binding protein 5 and modulating hepatocytes phenotype. Sci Rep 2016;6:25389. [PMID: 27138288 DOI: 10.1038/srep25389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
272 Sunami Y, Ringelhan M, Kokai E, Lu M, O'Connor T, Lorentzen A, Weber A, Rodewald AK, Müllhaupt B, Terracciano L, Gul S, Wissel S, Leithäuser F, Krappmann D, Riedl P, Hartmann D, Schirmbeck R, Strnad P, Hüser N, Kleeff J, Friess H, Schmid RM, Geisler F, Wirth T, Heikenwalder M. Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response. Hepatology 2016;63:1592-607. [PMID: 26892811 DOI: 10.1002/hep.28435] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
273 Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology 2016;63:1471-80. [PMID: 26509655 DOI: 10.1002/hep.28310] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
274 Cui AM, Cheng XY, Shao JG, Li HB, Wang XL, Shen Y, Mao LJ, Zhang S, Liu HY, Zhang L. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC Pregnancy Childbirth. 2016;16:87. [PMID: 27113723 DOI: 10.1186/s12884-016-0884-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
275 Huang J, Xiong L, Wang J, Liu Y, Zhu Q, Lei J, Zhou Z. Association between the HLA-DQB1 polymorphisms and the susceptibility of chronic hepatitis B: A comprehensive meta-analysis. Biomed Rep 2016;4:557-66. [PMID: 27123247 DOI: 10.3892/br.2016.632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
276 Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z, He J, Su L, Zhang L, Peng H, Fu YX. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. J Immunol 2016;196:3079-87. [PMID: 26936879 DOI: 10.4049/jimmunol.1502061] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
277 Yang J, Sheng G, Xiao D, Shi H, Wu W, Lu H, Cao H, Li L. The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment. Cell Mol Immunol. 2016;13:678-687. [PMID: 26899927 DOI: 10.1038/cmi.2015.100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
278 Uribe LA, Nguyen N, Kim L, Trinh HN, Wong C, Wong C, Nguyen LH, Nguyen MH. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. Dig Dis Sci 2016;61:618-25. [PMID: 26660679 DOI: 10.1007/s10620-015-3982-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
279 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
280 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
281 Wu YH. Naturally derived anti-hepatitis B virus agents and their mechanism of action. World J Gastroenterol 2016; 22(1): 188-204 [PMID: 26755870 DOI: 10.3748/wjg.v22.i1.188] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
282 Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, Olivero A, Marengo A, Rizzetto M, Bugianesi E, Smedile A. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis 2016;48:55-61. [PMID: 26514735 DOI: 10.1016/j.dld.2015.09.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
283 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1363] [Cited by in F6Publishing: 1174] [Article Influence: 194.7] [Reference Citation Analysis]
284 Nakanishi Y, Saxena R. Nonneoplastic Hepatobiliary Disease. Essentials of Anatomic Pathology 2016. [DOI: 10.1007/978-3-319-23380-2_44] [Reference Citation Analysis]
285 Vlachogiannakos J, Papatheodoridis GV. HBV: Do I treat my immunotolerant patients? Liver Int 2016;36 Suppl 1:93-9. [PMID: 26725904 DOI: 10.1111/liv.12996] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
286 Eed E, Khalifa A, Jaiash D, Shady A, El-saeed G, Ghonaim M, Makled A. Interleukins-10 and 18 Genes Polymorphisms in Hepatitis B Virus Infected Saudi Patients. Research J of Immunology 2016;9:1-8. [DOI: 10.3923/rji.2016.1.8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
287 Houri I, Shibolet O. Hepatocellular Carcinoma Associated with Hepatitis B Virus. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_16] [Reference Citation Analysis]
288 Zeng Q, Gong Y, Dong S, Xiang H, Wu Q. Association between exposure to hepatitis B virus and chronic kidney disease in China. J Int Med Res 2014;42:1178-84. [PMID: 25239876 DOI: 10.1177/0300060514541828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
289 Akbar SM, Al-Mahtab M, Jahan M, Yoshida O, Hiasa Y. Novel insights into immunotherapy for hepatitis B patients. Expert Rev Gastroenterol Hepatol 2016;10:267-76. [PMID: 26626120 DOI: 10.1586/17474124.2016.1112266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
290 Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to cure. Hepatology 2015;62:1893-908. [PMID: 26239691 DOI: 10.1002/hep.28025] [Cited by in Crossref: 221] [Cited by in F6Publishing: 202] [Article Influence: 27.6] [Reference Citation Analysis]
291 Lin CW, Huang XL, Liu HL, Wang Y. Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci 2015;60:3513-24. [PMID: 26112990 DOI: 10.1007/s10620-015-3772-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
292 Falcon-perez JM, Royo F. Circulating RNA: looking at the liver through a frosted glass. Biomarkers 2015;20:339-54. [DOI: 10.3109/1354750x.2015.1101785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
293 Makvandi K, Ranjbari N, Makvandi M, Ashraf Teimori A, Neisi N, Rasti M, Alipour V, Albokord M, Kanani M, Ahadi R. Study of the Association of Mutant HBsAg Gene and Hodgkin and Non-Hodgkin Lymphoma. Jundishapur J Microbiol. 2015;8:e25726. [PMID: 26862382 DOI: 10.5812/jjm.25726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
294 Jiang L, Hu S, Tian D, Zou X, He M. α-Mannosidase I Protein Expression in Peripheral Blood Mononuclear Cells Is Upregulated During Hepatitis B Virus Infection. Viral Immunol 2016;29:33-9. [PMID: 26569026 DOI: 10.1089/vim.2015.0079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
295 Behelgardi A, Hosseini SM, Mohebbi SR, Azimzadeh P, Derakhshani S, Karimi K, Sharifian A, Zali MR. A Study on Genetic Association of Interleukin-16 Single Nucleotide Polymorphism (rs1131445) With Chronic Hepatitis B Virus Infection in Iranian Patients. Jundishapur J Microbiol 2015;8:e23411. [PMID: 26855736 DOI: 10.5812/jjm.23411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
296 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol 2015; 21(42): 12141-12149 [PMID: 26576098 DOI: 10.3748/wjg.v21.i42.12141] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
297 Ozaras R, Corti G, Ruta S, Lacombe K, Mondelli M, Irwing W, Puoti M, Khalighi A, Santos M, Harxhi A, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends J. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical Microbiology and Infection 2015;21:1027-32. [DOI: 10.1016/j.cmi.2015.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
298 Moussa S, Brah S, Parola P, Gerolami R, Gamerre M, Boubli L, Ruiz JM, Ravaux I, Mokhtari S, Mancini J, Romera MH, Motte A, Tamalet C, Colson P. Epidemiological, clinical, virological features of hepatitis B newly diagnosed in 2011 in Marseille University hospitals, southeastern France. J Med Virol 2016;88:828-36. [PMID: 26439319 DOI: 10.1002/jmv.24398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
299 Tropberger P, Mercier A, Robinson M, Zhong W, Ganem DE, Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A 2015;112:E5715-24. [PMID: 26438841 DOI: 10.1073/pnas.1518090112] [Cited by in Crossref: 144] [Cited by in F6Publishing: 154] [Article Influence: 18.0] [Reference Citation Analysis]
300 Ringelhan M, Protzer U. Oncogenic potential of hepatitis B virus encoded proteins. Curr Opin Virol 2015;14:109-15. [PMID: 26426688 DOI: 10.1016/j.coviro.2015.08.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
301 O'Brien M, Casselman A, Smart G, Gretchen A, Kaita K, Kadkhoda K. Retrospective study of the prevalence and clinical significance of hepatitis B virus precore and basal core promoter variants. Can J Gastroenterol Hepatol 2015;29:e1-6. [PMID: 26401823 DOI: 10.1155/2015/940825] [Reference Citation Analysis]
302 Liang P, Zu J, Yin J, Li H, Gao L, Cui F, Wang F, Liang X, Zhuang G. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis. J Theor Biol. 2015;386:115-121. [PMID: 26375372 DOI: 10.1016/j.jtbi.2015.08.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
303 Goyal SK, Jain AK, Dixit VK, Shukla SK, Kumar M, Ghosh J, Ranjan A, Gupta N, Tripathi M. HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol 2015;5:213-20. [PMID: 26628839 DOI: 10.1016/j.jceh.2015.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
304 Oh IS, Park SH. Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Netw. 2015;15:191-198. [PMID: 26330805 DOI: 10.4110/in.2015.15.4.191] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
305 Li W, Jiang Y, Wang X, Jin J, Qi Y, Chi X, Zhang H, Feng X, Niu J. Natural Killer p46 Controls Hepatitis B Virus Replication and Modulates Liver Inflammation. PLoS One. 2015;10:e0135874. [PMID: 26291078 DOI: 10.1371/journal.pone.0135874] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
306 Ding W, Xin J, Jiang L, Zhou Q, Wu T, Shi D, Lin B, Li L, Li J. Characterisation of peripheral blood mononuclear cell microRNA in hepatitis B-related acute-on-chronic liver failure. Sci Rep. 2015;5:13098. [PMID: 26267843 DOI: 10.1038/srep13098] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
307 Pan HY, Pan HY, Chen L, Yang DH, Huang HJ, Tong YX, Chen CR, Yan J. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. Clin Microbiol Infect 2015;21:1123.e1-9. [PMID: 26253290 DOI: 10.1016/j.cmi.2015.07.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
308 Paraskevis D, Angelis K, Magiorkinis G, Kostaki E, Ho SY, Hatzakis A. Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes. Mol Phylogenet Evol 2015;93:44-54. [PMID: 26220838 DOI: 10.1016/j.ympev.2015.07.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
309 Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, Wang XM, Wang W, Lv DX, Li J, Deng YQ, Wang Y, Huo N, Yu M, Xi HL, Liu D, Zhou YX, Wang GQ, Xia NS, Zhang MX. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014;93:e322. [PMID: 25546679 DOI: 10.1097/MD.0000000000000322] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
310 Nikolova N, Jelev D, Antonov K, Mateva L, Krastev Z. The decrease of HBsAg during nucleos(t)ide analogues (NUC) therapy in Bulgarian patients. Biotechnology & Biotechnological Equipment 2015;29:746-752. [DOI: 10.1080/13102818.2015.1036773] [Reference Citation Analysis]
311 Goyal SK, Dixit VK, Shukla SK, Ghosh J, Behera M, Tripathi M, Gupta N, Ranjan A, Jain AK. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J Gastroenterol 2015;34:286-91. [PMID: 26243587 DOI: 10.1007/s12664-015-0576-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
312 van Vlerken LG, Arends P, Lieveld FI, Arends JE, Brouwer WP, Siersema PD, Janssen HL, van Erpecum KJ. Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis 2015;47:577-83. [PMID: 25936691 DOI: 10.1016/j.dld.2015.03.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
313 Wang HW, Gao HL, Wei XX, Wang XH. Up-regulation of IL-12 expression in patients with chronic hepatitis B is mediated by the PI3K/Akt pathway. Mol Cell Biochem. 2015;407:135-142. [PMID: 26062743 DOI: 10.1007/s11010-015-2463-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
314 Yin J, Ji Z, Liang P, Wu Q, Cui F, Wang F, Liang X, Zhuang G. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine 2015;33:3731-8. [PMID: 26057138 DOI: 10.1016/j.vaccine.2015.05.082] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
315 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
316 Wang YW, Shan X, Huang Y, Deng H, Huang WX, Zhang DZ, Chen J, Tang N, Shan YL, Guo JJ, Huang A. A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. Infect Genet Evol 2015;33:269-76. [PMID: 25983054 DOI: 10.1016/j.meegid.2015.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
317 Song L, Wang Y, Fang L, Wu Y, Yang L, Chen J, Ge S, Zhang J, Xiong Y, Deng X, Min X, Zhang J, Chen P, Yuan Q, Xia N. Rapid Fluorescent Lateral-Flow Immunoassay for Hepatitis B Virus Genotyping. Anal Chem 2015;87:5173-80. [DOI: 10.1021/ac504832c] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
318 McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38. [PMID: 25921660 DOI: 10.1016/j.cld.2015.01.001] [Cited by in Crossref: 474] [Cited by in F6Publishing: 489] [Article Influence: 59.3] [Reference Citation Analysis]
319 Heiberg IL, Pallett LJ, Winther TN, Høgh B, Maini MK, Peppa D. Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clin Exp Immunol 2015;179:466-76. [PMID: 25311087 DOI: 10.1111/cei.12470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
320 Yang J, Chen J, He J, Xie Y, Zhu Y, Cao H, Li L. Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection. Cell Mol Immunol 2014;11:332-42. [PMID: 25126662 DOI: 10.1038/cmi.2014.22] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
321 Mondal RK, Khatun M, Ghosh S, Banerjee P, Datta S, Sarkar S, Saha B, Santra A, Banerjee S, Chowdhury A, Datta S. Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation--an insight from human immunodeficiency virus/hepatitis B virus coinfection. Clin Microbiol Infect 2015; 21: 710.e11-710. e20. [PMID: 25882358 DOI: 10.1016/j.cmi.2015.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
322 González López Ledesma MM, Mojsiejczuk LN, Rodrigo B, Sevic I, Mammana L, Galdame O, Gadano A, Fainboim H, Campos R, Flichman D. Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina. PLoS One 2015;10:e0121436. [PMID: 25822666 DOI: 10.1371/journal.pone.0121436] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
323 Huang Y, Deng H, Shan X, Gong X, Li X, Tu Z, Long Q, Huang A. Lower mutation frequency of BCP/precore regions in e antigen-negative chronic HBV-infected children instead of adults patients. PLoS One. 2015;10:e0120733. [PMID: 25822176 DOI: 10.1371/journal.pone.0120733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
324 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
325 Ülger Y, Bayram S, Sandıkçı MÜ, Akgöllü E, Bekar A. Relationship between programmed cell death-1 polymorphisms and clearance of hepatitis B virus. Int J Immunogenet 2015;42:133-9. [PMID: 25736598 DOI: 10.1111/iji.12187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
326 Bockmann JH, Dandri M, Lüth S, Pannicke N, Lohse AW. Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure. World J Gastroenterol 2015; 21(7): 2214-2219 [PMID: 25717260 DOI: 10.3748/wjg.v21.i7.2214] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
327 Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235:355-367. [PMID: 25196558 DOI: 10.1002/path.4434] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 10.4] [Reference Citation Analysis]
328 Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015;19:1-22. [PMID: 25454294 DOI: 10.1016/j.cld.2014.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
329 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015;30:252-61. [PMID: 25318660 DOI: 10.1111/jgh.12831] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
330 Park YM. Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome. World J Hepatol 2015; 7(1): 113-120 [PMID: 25625002 DOI: 10.4254/wjh.v7.i1.113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
331 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
332 Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015;60:1457-64. [PMID: 25532501 DOI: 10.1007/s10620-014-3486-7] [Cited by in Crossref: 204] [Cited by in F6Publishing: 185] [Article Influence: 25.5] [Reference Citation Analysis]
333 Hepatitis B and D Virus Infections. Diagnostic Pathology: Infectious Diseases 2015. [DOI: 10.1016/b978-0-323-37677-8.50010-3] [Reference Citation Analysis]
334 Corder NLB, Koduru B, Park SB, Wang Y, Choi J. Oxidative Stress in Chronic Viral Hepatitis. Oxidative Stress in Applied Basic Research and Clinical Practice 2015. [DOI: 10.1007/978-3-319-15539-5_11] [Reference Citation Analysis]
335 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
336 Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J, Lu LL, Ni Z, Huang F, Yao H, Zhu J, Fan J, Zhu Y, Wu Z, Liu G, Gao W, Zang M, Wang D, Dai M, Hsia CC, Zhang Y, Sun Z. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014;11:e1001774. [PMID: 25549238 DOI: 10.1371/journal.pmed.1001774] [Cited by in Crossref: 80] [Cited by in F6Publishing: 92] [Article Influence: 8.9] [Reference Citation Analysis]
337 Bahnassy AA, Zekri ARN, El-Bastawisy A, Fawzy A, Shetta M, Hussein N, Omran D, Ahmed AAS, El-Labbody SS. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. World J Gastroenterol 2014; 20(48): 18240-18248 [PMID: 25561791 DOI: 10.3748/wjg.v20.i48.18240] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
338 Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204:5-10. [PMID: 25540037 DOI: 10.1007/s00430-014-0369-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
339 Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
340 Yang J, Lu H, Guo R, Yan D, Ye P, Jin L, Chen C, Cao H, Diao H, Li L. Molecular profile of the T cell receptor beta variable in peripheral blood lymphocytes from chronic asymptomatic HBV carriers. Pathogens and Disease 2014;73:1-9. [DOI: 10.1093/femspd/ftu018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
341 Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Selabe SG, Gededzha MP, Mayaphi SH, Powell EA, Blackard JT, Mphahlele MJ. Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants. J Clin Virol 2015;63:12-7. [PMID: 25600597 DOI: 10.1016/j.jcv.2014.11.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
342 Tanaka M, Gehan E, Chen MY, Wang JH. Hepatitis B screening practice among older Chinese in the Greater Washington, DC, area. South Med J 2014;107:655-60. [PMID: 25279872 DOI: 10.14423/SMJ.0000000000000177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
343 Ringelhan M, Reisinger F, Yuan D, Weber A, Heikenwalder M. Modeling human liver cancer heterogeneity: virally induced transgenic models and mouse genetic models of chronic liver inflammation. Curr Protoc Pharmacol 2014;67:14.31.1-14.31.17. [PMID: 25446288 DOI: 10.1002/0471141755.ph1431s67] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
344 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
345 Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785-794. [PMID: 25384794 DOI: 10.1007/s00535-014-1010-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
346 Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, Chayama K. Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect. 2015;70:273-287. [PMID: 25452043 DOI: 10.1016/j.jinf.2014.10.017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
347 Huang C, Zheng JM, Cheng Q, Yu KK, Ling QX, Chen MQ, Li N. Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection. J Dig Dis 2014;15:614-21. [PMID: 25138057 DOI: 10.1111/1751-2980.12185] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
348 Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect 2015;21:197-203. [PMID: 25658546 DOI: 10.1016/j.cmi.2014.10.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 8.8] [Reference Citation Analysis]
349 Catamo E, Zupin L, Crovella S, Celsi F, Segat L. Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Hum Immunol 2014;75:1225-31. [PMID: 25318079 DOI: 10.1016/j.humimm.2014.09.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
350 Zhao X, Wu Y, Duan J, Ma Y, Shen Z, Wei L, Cui X, Zhang J, Xie Y, Liu J. Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC–MS/MS. J Proteome Res 2014;13:5391-402. [DOI: 10.1021/pr5008703] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
351 Spradling PR, Bulkow L, Teshale EH, Negus S, Homan C, Simons B, McMahon BJ. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. J Hepatol 2014;61:785-91. [PMID: 24911461 DOI: 10.1016/j.jhep.2014.05.045] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
352 Heidrich B, Cetindere A, Beyaz M, Stahmeyer JT, Basaran MM, Braynis B, Raupach R, Bremer B, Manns MP, Wedemeyer H, Bastürk M. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol 2014;26:1090-7. [PMID: 25076065 DOI: 10.1097/MEG.0000000000000164] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
353 Liu C, Chen S, Wang X, Chen Y, Tang N. 15d-PGJ2 decreases PGE2 synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter. Biochemical Pharmacology 2014;91:337-47. [DOI: 10.1016/j.bcp.2014.07.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
354 Li Z, Xie Z, Ni H, Zhang Q, Lu W, Yin J, Liu W, Ding Y, Zhao Y, Zhu Y, Pu R, Zhang H, Dong H, Fu Y, Sun Q, Xu G, Cao G. Mother-to-child transmission of hepatitis B virus: Evolution of hepatocellular carcinoma-related viral mutations in the post-immunization era. Journal of Clinical Virology 2014;61:47-54. [DOI: 10.1016/j.jcv.2014.06.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
355 Kevorkyan A, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011. J Med Virol. 2015;87:401-406. [PMID: 25163778 DOI: 10.1002/jmv.24065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
356 Amano K, Kawaguchi T, Kuromatsu R, Kawaguchi A, Miyajima I, Ide T, Kakuma T, Sata M. Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. Mol Clin Oncol 2014;2:927-34. [PMID: 25279176 DOI: 10.3892/mco.2014.398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
357 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol 2014; 20(30): 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.8] [Reference Citation Analysis]
358 Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol 2014; 6(7): 504-512 [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
359 Doganay L, Fejzullahu A, Katrinli S, Enc FY, Ozturk O, Colak Y, Ulasoglu C, Tuncer I, Doganay GD. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. World J Gastroenterol 2014; 20(25): 8179-8186 [PMID: 25009391 DOI: 10.3748/wjg.v20.i25.8179] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
360 Zhu L, Zhai X, Zhu Y, Xu W, Bao C, Peng H, Bian Q, Yang H, Wang H, Hu Z, Shen H. Evaluation of the impact of hepatitis B vaccination in adults in Jiangsu province, China. PLoS One 2014;9:e101501. [PMID: 24979048 DOI: 10.1371/journal.pone.0101501] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
361 Sun W, Su Q, Cao X, Shang B, Chen A, Yin H, Liu B. High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma. Int J Genomics. 2014;2014:312130. [PMID: 25019081 DOI: 10.1155/2014/312130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
362 Tanaka M, Strong C, Lee S, Juon HS. Influence of information sources on hepatitis B screening behavior and relevant psychosocial factors among Asian immigrants. J Immigr Minor Health 2013;15:779-87. [PMID: 23238580 DOI: 10.1007/s10903-012-9753-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
363 Martín-mateos RM, Moreira Vicente VF, Téllez-villajos L, García-sánchez C, Maroto-castellanos MT, García-alonso FJ, Mateos-lindemann ML, Albillos A. Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica. Gastroenterología y Hepatología 2014;37:280-8. [DOI: 10.1016/j.gastrohep.2013.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
364 Zhang Q, Shang L, Zang Y, Chen X, Zhang L, Wang Y, Wang L, Liu Y, Mao S, Shen Z. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation. Eur J Gastroenterol Hepatol 2014;26:544-52. [PMID: 24614696 DOI: 10.1097/MEG.0000000000000029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
365 Wu Y, Gan Y, Gao F, Zhao Z, Jin Y, Zhu Y, Sun Z, Wu H, Chen T, Wang J. Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma. PLoS One. 2014;9:e94864. [PMID: 24788140 DOI: 10.1371/journal.pone.0094864] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
366 Mekky MA. To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy. World J Hepatol 2014; 6(4): 226-229 [PMID: 24799991 DOI: 10.4254/wjh.v6.i4.226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
367 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
368 Soriano V, de Mendoza C, Fernández-montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. Annals of Medicine 2014;46:290-6. [DOI: 10.3109/07853890.2014.899103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
369 Hosseini Razavi A, Azimzadeh P, Mohebbi SR, Hosseini SM, Romani S, Khanyaghma M, Hatami Y, Sharifian A, Zali MR. Lack of Association Between Transforming Growth Factor Beta 1 -509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients. Hepat Mon 2014;14:e13100. [PMID: 24748892 DOI: 10.5812/hepatmon.13100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
370 Sun XR, Wu J, Tang KF. The interferon-gamma (IFN-γ) +874T allele reduces the risk of hepatitis B infection in an Asian population. J Viral Hepat 2014;21:281-7. [PMID: 24597696 DOI: 10.1111/jvh.12140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
371 Song G, Jia H, Xu H, Liu W, Zhu H, Li S, Shi J, Li Z, He J, Chen Z. Studying the association of microRNA-210 level with chronic hepatitis B progression. J Viral Hepat 2014;21:272-80. [PMID: 24597695 DOI: 10.1111/jvh.12138] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
372 Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014;9:e93160. [PMID: 24682088 DOI: 10.1371/journal.pone.0093160] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
373 Sohn W, Paik Y, Kim JM, Kwon CH, Joh JW, Cho JY, Gwak G, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:2429-35. [DOI: 10.1245/s10434-014-3621-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
374 Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol 2014;49:373-80. [PMID: 24354931 DOI: 10.3109/00365521.2013.871745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
375 Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele MJ. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J Med Virol 2014;86:918-24. [PMID: 24615635 DOI: 10.1002/jmv.23910] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
376 Yim SY, Um SH, Jung JY, Seo YS, Yim HJ, Ryu HS, Chun HJ, Jeen YT, Kim CD, Keum B, Lee HS. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus. J Clin Gastroenterol 2014;48:166-71. [PMID: 24045280 DOI: 10.1097/MCG.0b013e3182a4711d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
377 Ismail AM, Puhazhenthi KS, Sivakumar J, Eapen CE, Kannangai R, Abraham P. Molecular epidemiology and genetic characterization of hepatitis B virus in the Indian subcontinent. Int J Infect Dis. 2014;20:1-10. [PMID: 24445226 DOI: 10.1016/j.ijid.2013.12.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
378 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 203] [Cited by in F6Publishing: 224] [Article Influence: 22.6] [Reference Citation Analysis]
379 Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int 2014;8:39-54. [PMID: 26202405 DOI: 10.1007/s12072-013-9495-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
380 Robotis J, Vassilaki N. Viral Hepatitis☆. Reference Module in Biomedical Sciences 2014. [DOI: 10.1016/b978-0-12-801238-3.05401-5] [Reference Citation Analysis]
381 Evans AA, Cohen C, Block TM. Hepatitis Viruses: Hepatitis B and Hepatitis D. Viral Infections of Humans 2014. [DOI: 10.1007/978-1-4899-7448-8_32] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
382 Shah U. Infections of the Liver. Diseases of the Liver in Children 2014. [DOI: 10.1007/978-1-4614-9005-0_15] [Reference Citation Analysis]
383 Kew MC. Hepatitis B Virus: Epidemiology and Clinical Features of Related Cancer. Viruses and Human Cancer 2014. [DOI: 10.1007/978-1-4939-0870-7_7] [Reference Citation Analysis]
384 Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014;21:662-70. [PMID: 24329883 DOI: 10.1111/jvh.12202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
385 Delfino CM, Gentile EA, Castillo AI, Cuestas ML, Pataccini G, Cánepa C, Malan R, Blejer J, Berini C, Eirin ME, Pedrozo W, Oubiña JR, Biglione MM, Mathet VL. Hepatitis B virus and hepatitis D virus in blood donors from Argentina: circulation of HBsAg and reverse transcriptase mutants. Arch Virol 2014;159:1109-17. [DOI: 10.1007/s00705-013-1917-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
386 Jain N, Rajoriya V, Jain PK, Jain AK. Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir. J Nanopart Res 2014;16. [DOI: 10.1007/s11051-013-2136-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
387 Luo ZH, Zou J, Mi L, Liu Y, Tong YL, Yu XF. Evaluation of hepatic fibrosis stage (≥ F2) by fibroscan in patients with chronic viral hepatitis: A Meta-analysis. Shijie Huaren Xiaohua Zazhi 2013; 21(33): 3724-3735 [DOI: 10.11569/wcjd.v21.i33.3724] [Reference Citation Analysis]
388 Hansen N, Hay G, Cowan S, Jepsen P, Bygum Krarup H, Obel N, Weis N, Brehm Christensen P. Hepatitis B prevalence in Denmark - an estimate based on nationwide registers and a national screening programme, as on 31 December 2007. Euro Surveill 2013;18:20637. [PMID: 24300884 DOI: 10.2807/1560-7917.es2013.18.47.20637] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
389 Ruan P, Yang C, Su J, Cao J, Ou C, Luo C, Tang Y, Wang Q, Yang F, Shi J, Lu X, Zhu L, Qin H, Sun W, Lao Y, Li Y. Histopathological changes in the liver of tree shrew (Tupaia belangeri chinensis) persistently infected with hepatitis B virus. Virol J 2013;10:333. [PMID: 24220021 DOI: 10.1186/1743-422X-10-333] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
390 Winther TN, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLoS One 2013;8:e80384. [PMID: 24244683 DOI: 10.1371/journal.pone.0080384] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
391 Teriaky A, Al-Judaibi B. Correlation between HBsAg quantitation and HBV DNA in HBeAg-negative HBV/D patients. Saudi J Gastroenterol 2013;19:243-4. [PMID: 24195976 DOI: 10.4103/1319-3767.121030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
392 Wang L, Pan Y, Zhang K, Zhang R, Sun Y, Xie J, Li J. A 10-year human hepatitis B virus nucleic test external quality assessment in China: continual improvement. Clin Chim Acta 2013;425:139-47. [PMID: 23916788 DOI: 10.1016/j.cca.2013.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
393 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
394 Zhang X, Chang Li X, Xiao X, Sun R, Tian Z, Wei H. CD4(+)CD62L(+) central memory T cells can be converted to Foxp3(+) T cells. PLoS One 2013;8:e77322. [PMID: 24155942 DOI: 10.1371/journal.pone.0077322] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
395 Zhang X, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet. 2013;4:202. [PMID: 24133502 DOI: 10.3389/fgene.2013.00202] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
396 Martinot-peignoux M, Lapalus M, Laouénan C, Lada O, Netto-cardoso ACF, Boyer N, Ripault MP, Carvalho-filho R, Asselah T, Marcellin P. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. Journal of Clinical Virology 2013;58:401-7. [DOI: 10.1016/j.jcv.2013.08.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
397 Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013;15:311-7. [PMID: 23529864 DOI: 10.1007/s40272-013-0010-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
398 Zheng YB, Huang ZL, Wu ZB, Zhang M, Gu YR, Su YJ, Lin CS, Zhu RH, Lin BL, Gao ZL. Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study. Int J Med Sci. 2013;10:1658-1664. [PMID: 24151437 DOI: 10.7150/ijms.6415] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
399 Xia P, Zhou M, Dong DS, Xing YN, Bai Y. Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis. Tumour Biol 2014;35:1129-37. [PMID: 24026885 DOI: 10.1007/s13277-013-1151-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
400 Arataki K, Hayes CN, Akamatsu S, Akiyama R, Abe H, Tsuge M, Miki D, Ochi H, Hiraga N, Imamura M. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol. 2013;85:789-798. [PMID: 23508904 DOI: 10.1002/jmv.23540] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
401 Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 2013;58:890-901. [PMID: 23505208 DOI: 10.1002/hep.26383] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
402 Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol. 2013;58:396-400. [PMID: 24001884 DOI: 10.1016/j.jcv.2013.08.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
403 Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013;43:1069-1083. [PMID: 23927644 DOI: 10.1111/eci.12128] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
404 Yao JJ, Yu JL, Li J, Chen M, Yang H, Song QL, Lin JS. Association of a HLA-DP gene polymorphism with progression of HBV infection. Shijie Huaren Xiaohua Zazhi 2013; 21(22): 2206-2211 [DOI: 10.11569/wcjd.v21.i22.2206] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
405 Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol 2013;47:644-50. [PMID: 23442843 DOI: 10.1097/MCG.0b013e3182896abf] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
406 Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis 2013;17:399-412. [PMID: 23905812 DOI: 10.1016/j.cld.2013.05.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
407 Zhang X, Xing H, Feng X, Zhang H, Wang Y, Yan H. Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1). Virol J 2013;10:232. [PMID: 23849342 DOI: 10.1186/1743-422X-10-232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
408 Peng L, Guo J, Zhang Z, Liu L, Cao Y, Shi H, Wang J, Wang J, Friedman SL, Sninsky JJ. A candidate gene study for the association of host single nucleotide polymorphisms with liver cirrhosis risk in chinese hepatitis B patients. Genet Test Mol Biomarkers 2013;17:681-6. [PMID: 23844940 DOI: 10.1089/gtmb.2013.0058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
409 Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A, Sagnelli E. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 2013;8:e65336. [PMID: 23843939 DOI: 10.1371/journal.pone.0065336] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
410 Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon 2013;13:e8351. [PMID: 24066001 DOI: 10.5812/hepatmon.8351] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
411 Al-Naamani K, Al-Maqbali A, Al-Sinani S. Characteristics of hepatitis B infection in a sample of omani patients. Sultan Qaboos Univ Med J 2013;13:380-5. [PMID: 23984022 DOI: 10.12816/0003259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
412 Geng XX, Lin JM, Yang XX, Huang RG, Jiang N. Liver histopathology and clinical manifestations between HBeAg-positive and -negative patients with chronic HBV infection and mildly elevated ALT level (less than two-time up limit of normal): An analysis of 196 cases. Shijie Huaren Xiaohua Zazhi 2013; 21(17): 1607-1615 [DOI: 10.11569/wcjd.v21.i17.1607] [Reference Citation Analysis]
413 Ringelhan M, Heikenwalder M, Protzer U. Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. Dig Dis 2013;31:138-51. [PMID: 23797136 DOI: 10.1159/000347209] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
414 Wu T, Chu C, Ho T, Chang Liao H, Lin S, Lin M, Lin HH, Wang L. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Hum Genet 2013;132:1131-9. [DOI: 10.1007/s00439-013-1320-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
415 Zhang XL, Ni XC, Jia JH, Dong JH, Yu FX, Ma N, Liu XH, Li M, Liu DW. Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: a meta-analysis. Scand J Gastroenterol 2013;48:736-44. [PMID: 23601003 DOI: 10.3109/00365521.2013.787643] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
416 Li Y, Xie J, Xu X, Liu L, Wan Y, Liu Y, Zhu C, Zhu Y. Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1). J Biol Chem 2013;288:20927-41. [PMID: 23729669 DOI: 10.1074/jbc.M112.440115] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
417 Du X, Wang J, Shao L, Hu X, Yang C, Shen L, Weng X, Zhang W. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepat 2013;20:328-35. [PMID: 23565615 DOI: 10.1111/jvh.12034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
418 Jung YJ, Kim JW, Park SJ, Min BY, Jang ES, Kim NY, Jeong SH, Shin CM, Lee SH, Park YS. c-Myc-mediated overexpression of miR-17-92 suppresses replication of hepatitis B virus in human hepatoma cells. J Med Virol. 2013;85:969-978. [PMID: 23532756 DOI: 10.1002/jmv.23534] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
419 Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest. 2013;73:300-308. [PMID: 23514016 DOI: 10.3109/00365513.2013.773592] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
420 Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B. Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. PLoS One 2013;8:e58236. [PMID: 23469271 DOI: 10.1371/journal.pone.0058236] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
421 Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013;33 Suppl 1:125-32. [PMID: 23286856 DOI: 10.1111/liv.12075] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
422 Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, Bonanni P. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother 2013;9:1119-28. [PMID: 23376840 DOI: 10.4161/hv.23827] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
423 Kondo Y, Ninomiya M, Kakazu E, Kimura O, Shimosegawa T. Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection. ISRN Gastroenterol. 2013;2013:935295. [PMID: 23401786 DOI: 10.1155/2013/935295] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
424 Strong C, Lee S, Tanaka M, Juon HS. Ethnic differences in prevalence and barriers of HBV screening and vaccination among Asian Americans. J Community Health 2012;37:1071-80. [PMID: 22302652 DOI: 10.1007/s10900-012-9541-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
425 Hulstaert F, Schwierz C, Nevens F, Thiry N, Gamil M, Colle I, Van de Sande S, Horsmans Y. SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE? Int J Technol Assess Health Care 2013;29:35-41. [DOI: 10.1017/s0266462312000736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
426 Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic promise. Yonsei Med J. 2012;53:875-885. [PMID: 22869468 DOI: 10.3349/ymj.2012.53.5.875] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
427 Strickland GT, El-kamary SS. Viral Hepatitis. Hunter's Tropical Medicine and Emerging Infectious Disease 2013. [DOI: 10.1016/b978-1-4160-4390-4.00031-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
428 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
429 Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One. 2012;7:e50919. [PMID: 23236406 DOI: 10.1371/journal.pone.0050919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
430 Khorramdelazad H, Hassanshahi G, Nasiri Ahmadabadi B, Kazemi Arababadi M. High Serum Levels of TGF-β in Iranians With Chronic HBV Infection. Hepat Mon 2012;12:e7581. [PMID: 23346151 DOI: 10.5812/hepatmon.7581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
431 Simon B, Kundi M, Puchhammer E. Analysis of mutations in the S gene of hepatitis B virus strains in patients with chronic infection by online bioinformatics tools. J Clin Microbiol 2013;51:163-8. [PMID: 23115258 DOI: 10.1128/JCM.01630-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
432 Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, Chayama K. Hepatitis B virus-specific MiRNA s and Argonaute2 play a role in the viral life cycle. PLoS One. 2012;7:e47490. [PMID: 23091627 DOI: 10.1371/journal.pone.0047490] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
433 Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. J Hepatol 2012;57:885-96. [PMID: 22634122 DOI: 10.1016/j.jhep.2012.03.036] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
434 Indolfi G, Nesi A, Resti M. Treatment of chronic hepatitis B and C in children. Future Virology 2012;7:955-72. [DOI: 10.2217/fvl.12.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
435 Aoki J, Kowazaki Y, Ohtsuki T, Okamoto R, Ohashi K, Hayashi S, Sakamaki H, Kohara M, Kimura K. Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. J Gastroenterol. 2013;48:728-737. [PMID: 23011082 DOI: 10.1007/s00535-012-0676-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
436 Durantel D, Zoulim F. Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option? J Hepatol 2012;57:486-9. [PMID: 22728561 DOI: 10.1016/j.jhep.2012.06.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
437 Cai J, Fan X, Mou L, Gao B, Liu X, Li J, Liu L, Wang H, Guo Z, Liu X, Li H, Li X, Li X. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. Clin J Am Soc Nephrol 2012;7:1561-6. [PMID: 22859746 DOI: 10.2215/CJN.07410711] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
438 Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012;19:581-93. [PMID: 22762143 DOI: 10.1111/j.1365-2893.2012.01589.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
439 Baha W, Ennaji MM, Lazar F, Melloul M, El Fahime E, El Malki A, Bennani A. HBV genotypes prevalence, precore and basal core mutants in Morocco. Infection, Genetics and Evolution 2012;12:1157-62. [DOI: 10.1016/j.meegid.2012.04.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
440 Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, Olagüe C, Vales A, Riezu JI, Larrea E, Borras F, Benito A, Hernandez-Alcoceba R, Menne S, Prieto J, González-Aseguinolaza G. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology 2012;56:474-83. [PMID: 22334260 DOI: 10.1002/hep.25667] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
441 Ciupe SM, Hews S. Mathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection. PLoS One 2012;7:e39591. [PMID: 22768303 DOI: 10.1371/journal.pone.0039591] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
442 Wiegand J, Kühne M, Pradat P, Mössner J, Trepo C, Tillmann HL. Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Aliment Pharmacol Ther 2012;35:1443-50. [PMID: 22530565 DOI: 10.1111/j.1365-2036.2012.05108.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
443 Delfino CM, Berini C, Eirin ME, Malan R, Pedrozo W, Krupp R, Blejer J, Espejo R, Fierro L, Puca A, Oubiña JR, Mathet VL, Biglione MM. New natural variants of hepatitis B virus among Amerindians from Argentina with mainly occult infections. Journal of Clinical Virology 2012;54:174-9. [DOI: 10.1016/j.jcv.2012.02.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
444 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
445 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
446 Martín Mateos R, García-alonso F, Moreira Vicente V. Hepatitis crónica por virus B. Historia natural y tratamiento. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:521-528. [DOI: 10.1016/s0304-5412(12)70342-6] [Reference Citation Analysis]
447 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
448 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 102] [Cited by in F6Publishing: 111] [Article Influence: 9.3] [Reference Citation Analysis]
449 Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol 2012;56:795-802. [PMID: 22173170 DOI: 10.1016/j.jhep.2011.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
450 Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:2511-2529. [PMID: 22141390 DOI: 10.2165/11208510-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
451 Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 2012;8:e1002594. [PMID: 22438812 DOI: 10.1371/journal.ppat.1002594] [Cited by in Crossref: 143] [Cited by in F6Publishing: 151] [Article Influence: 13.0] [Reference Citation Analysis]
452 Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012;19:220-6. [PMID: 22329377 DOI: 10.1111/j.1365-2893.2011.01542.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
453 Cheng CP, Lee PF, Liu WC, Wu IC, Chin CY, Chang TT, Tseng VS. Analysis of precore/core covariances associated with viral kinetics and genotypes in hepatitis B e antigen-positive chronic hepatitis B patients. PLoS One 2012;7:e32553. [PMID: 22384271 DOI: 10.1371/journal.pone.0032553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
454 Zheng MH, Xiao DD, Lin XF, Wu SJ, Peng MM, Yu XY, Liu WY, Li LF, Shi KQ, Fan YC, Chen YP. The tumour necrosis factor-α-238A allele increases the risk of chronic HBV infection in European populations. J Viral Hepat 2012;19:e11-7. [PMID: 22239507 DOI: 10.1111/j.1365-2893.2011.01491.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
455 Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 2012;79:302-305. [PMID: 22239156 DOI: 10.1111/j.1399-0039.2011.01835.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
456 Shimomura S, Nishiguchi S. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2012;42:22-32. [PMID: 21951512 DOI: 10.1111/j.1872-034X.2011.00889.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
457 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
458 Byrd KK, Murphy TV, Hu DJ. Hepatitis B and Hepatitis D Viruses. Principles and Practice of Pediatric Infectious Diseases 2012. [DOI: 10.1016/b978-1-4377-2702-9.00215-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
459 Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012;107:133-8. [PMID: 21876562 DOI: 10.1038/ajg.2011.295] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
460 Roll GR, Roberts J. Liver transplantation for hepatocellular carcinoma. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract 2012. [DOI: 10.1016/b978-1-4377-1454-8.00141-7] [Reference Citation Analysis]
461 Theise ND, Bodenheimer HC, Ferrell LD. Acute and chronic viral hepatitis. MacSween's Pathology of the Liver 2012. [DOI: 10.1016/b978-0-7020-3398-8.00007-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
462 Yang J, He J, Lu H, Wei L, Li S, Wang B, Diao H, Li L. Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B. J Transl Med 2011;9:210. [PMID: 22152113 DOI: 10.1186/1479-5876-9-210] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
463 Fatima G, Mathan G, Kumar V. The HBx protein of hepatitis B virus regulates the expression, intracellular distribution and functions of ribosomal protein S27a. J Gen Virol 2012;93:706-15. [PMID: 22158882 DOI: 10.1099/vir.0.035691-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
464 Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Digestion 2011;84 Suppl 1:23-8. [PMID: 22156482 DOI: 10.1159/000333211] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
465 Mcmahon BJ, Simons BC, Livingston SE. Update on Diagnosis and Treatment within the Four Clinical Phases of Chronic Hepatitis B Infection. Curr Hepatitis Rep 2011;10:229-234. [DOI: 10.1007/s11901-011-0110-6] [Reference Citation Analysis]
466 Wang FB, Zhu CL, Liu X, Gao GS. HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis 2011;10:207. [PMID: 22074108 DOI: 10.1186/1476-511X-10-207] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
467 [DOI: 10.1109/taai.2011.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
468 Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011;56:3143-62. [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
469 Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-31. [PMID: 21718667 DOI: 10.1016/j.jhep.2011.06.006] [Cited by in Crossref: 229] [Cited by in F6Publishing: 229] [Article Influence: 19.1] [Reference Citation Analysis]
470 Li M, Sun XH, Zhu XJ, Jin SG, Zeng ZJ, Zhou ZH, Yu Z, Gao YQ. HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Lab Invest. 2012;92:295-304. [PMID: 22042085 DOI: 10.1038/labinvest.2011.157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
471 Børresen ML, Koch A, Biggar RJ, Andersson M, Wohlfahrt J, Ladefoged K, Melbye M. Hepatocellular carcinoma and other liver disease among Greenlanders chronically infected with hepatitis B virus: a population-based study. J Natl Cancer Inst. 2011;103:1676-1685. [PMID: 22021665 DOI: 10.1093/jnci/djr405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
472 Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL–HBV) Study Group. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-8, 1248.e1-2. [PMID: 21703214 DOI: 10.1053/j.gastro.2011.06.036] [Cited by in Crossref: 175] [Cited by in F6Publishing: 184] [Article Influence: 14.6] [Reference Citation Analysis]
473 Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol 2012;5:270-82. [PMID: 21958338 DOI: 10.1111/j.1751-7915.2011.00303.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
474 Nakamura Y, Mizuguchi T, Kawamoto M, Meguro M, Harada K, Ota S, Hirata K. Cluster analysis of indicators of liver functional and preoperative low branched-chain amino acid tyrosine ration indicate a high risk of early recurrence in analysis of 165 hepatocellular carcinoma patients after initial hepatectomy. Surgery. 2011;150:250-262. [PMID: 21801962 DOI: 10.1016/j.surg.2011.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
475 Farnik H, Lange CM, Hofmann WP, Berger A, Allwinn R, Welker MW, Trojan J, Sarrazin C, Herrmann E, Zeuzem S, Kronenberger B. Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. J Clin Virol 2011;52:204-9. [PMID: 21903459 DOI: 10.1016/j.jcv.2011.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
476 McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011;54:801-7. [PMID: 21618565 DOI: 10.1002/hep.24442] [Cited by in Crossref: 136] [Cited by in F6Publishing: 124] [Article Influence: 11.3] [Reference Citation Analysis]
477 Wang J, Zhou B, Lai Q, Wang Y, Shen G, Wang Z, Chen J, Hou J. Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E antigen and antibody detection. J Viral Hepat 2011;18:646-52. [PMID: 20636332 DOI: 10.1111/j.1365-2893.2010.01345.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
478 Horvat RT. Diagnostic and Clinical Relevance of HBV Mutations. Lab Med 2011;42:488-96. [DOI: 10.1309/lm7sf4qzmeg5lvpn] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
479 Massoumi H, Martin P, Tan HH. Management of chronic hepatitis B. Eur J Gastroenterol Hepatol 2011;23:642-50. [PMID: 21602690 DOI: 10.1097/MEG.0b013e3283474add] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
480 Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010;3:107-19. [PMID: 21180595 DOI: 10.1177/1756283X09354562] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
481 Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, Hosono N, Takahashi A, Kamatani Y, Miki D, Abe H. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet. 2011;20:3884-3892. [PMID: 21750111 DOI: 10.1093/hmg/ddr301] [Cited by in Crossref: 165] [Cited by in F6Publishing: 178] [Article Influence: 13.8] [Reference Citation Analysis]
482 Shi WW, Lin A, Xu DP, Bao WG, Zhang JG, Chen SY, Li J, Yan WH. Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection. Hum Immunol. 2011;72:1068-1073. [PMID: 21762747 DOI: 10.1016/j.humimm.2011.06.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
483 Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011;55:183-91. [PMID: 21238520 DOI: 10.1016/j.jhep.2010.12.030] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 10.2] [Reference Citation Analysis]
484 Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Mendy M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G; World Health Organization Department of Immunization, Vaccines and Biologicals. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011;31:755-61. [PMID: 21645206 DOI: 10.1111/j.1478-3231.2010.02373.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
485 Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat 2011;18:e200-5. [PMID: 21692933 DOI: 10.1111/j.1365-2893.2010.01428.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
486 Khokhlova NI, Tolokonskaya NP, Pupyshev AB. Multifactor clinical-laboratory valuation of endogenic intoxication in chronic hepatitis B. Bûll sib med 2011;10:139-144. [DOI: 10.20538/1682-0363-2011-3-139-144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
487 Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, Tsongalis GJ, Wang YF, Yen-Lieberman B, Young S, Lurain NS. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol 2011;49:2854-8. [PMID: 21697326 DOI: 10.1128/JCM.00471-11] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
488 Zhao WF, Chen LY. Viral hepatitis B in children: clinical characteristics and antiviral treatment. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1624-1628 [DOI: 10.11569/wcjd.v19.i15.1624] [Reference Citation Analysis]
489 Horvat RT, Tegtmeier GE. Hepatitis B and D Viruses. Manual of Clinical Microbiology 2011. [DOI: 10.1128/9781555816728.ch106] [Reference Citation Analysis]
490 Nie H, Evans AA, London WT, Block TM, Ren XD. Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol 2011;49:2440-8. [PMID: 21562108 DOI: 10.1128/JCM.02472-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
491 Saddic LA, Wirt S, Vogel H, Felsher DW, Sage J. Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One 2011;6:e19758. [PMID: 21573126 DOI: 10.1371/journal.pone.0019758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
492 Ko HH, Wong DK, Heathcote J. Management of hepatitis B. Clin Gastroenterol Hepatol 2011;9:385-91. [PMID: 21185398 DOI: 10.1016/j.cgh.2010.12.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
493 Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011;54:879-86. [PMID: 21145812 DOI: 10.1016/j.jhep.2010.08.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
494 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x. [PMID: 21689610 DOI: 10.1016/j.cld.2011.03.006] [Cited by in Crossref: 319] [Cited by in F6Publishing: 331] [Article Influence: 26.6] [Reference Citation Analysis]
495 Lee JH, Han KH, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol. 2011;18:914-921. [PMID: 21490166 DOI: 10.1128/cvi.00474-10] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
496 Ledesma MM, Galdame O, Bouzas B, Tadey L, Livellara B, Giuliano S, Viaut M, Paz S, Fainboim H, Gadano A, Campos R, Flichman D. Characterization of the basal core promoter and precore regions in anti-HBe-positive inactive carriers of hepatitis B virus. Int J Infect Dis 2011;15:e314-20. [PMID: 21367634 DOI: 10.1016/j.ijid.2010.12.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
497 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:619-33. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
498 Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP. Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol. 2011;83:791-795. [PMID: 21360547 DOI: 10.1002/jmv.22043] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
499 Xiang Y, Huang S, Xia J, Ye D, Chen P, Zhang L. Characterization of hepatitis B virus molecular genotypes in Chongqing and quantitative serological markers in patients during natural phases of chronic hepatitis B infection. Intervirology. 2012;55:68-72. [PMID: 21293110 DOI: 10.1159/000323524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
500 Kim JW, Lee SH, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011;54:316-325. [PMID: 21242658 DOI: 10.1159/000321450] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
501 Pang R, Tao JY, Zhang SL, Chen KL, Zhao L, Yue X, Wang YF, Ye P, Zhu Y, Wu JG. Ethanol Extract from Ampelopsis sinica Root Exerts Anti-Hepatitis B Virus Activity via Inhibition of p53 Pathway In Vitro. Evid Based Complement Alternat Med 2011;2011:939205. [PMID: 21738555 DOI: 10.1093/ecam/neq011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
502 Saxena R. Nonneoplastic Hepatobiliary Disease. Essentials of Anatomic Pathology 2011. [DOI: 10.1007/978-1-4419-6043-6_44] [Reference Citation Analysis]
503 Kanel GC, Korula J. Viral Hepatitis. Atlas of Liver Pathology 2011. [DOI: 10.1016/b978-1-4377-0765-6.10002-3] [Reference Citation Analysis]
504 Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43. [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011] [Cited by in Crossref: 346] [Cited by in F6Publishing: 373] [Article Influence: 28.8] [Reference Citation Analysis]
505 Cornberg M, Manns M. Leitliniengerechte Therapie der Hepatitis B. Korrekte Indikationsstellung ist die Voraussetzung. Pharmazie in unserer Zeit 2011;40:45-51. [DOI: 10.1002/pauz.201100399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
506 Ilan Y. A fourth dimension in decision making in hepatology. Hepatol Res 2010;40:1143-54. [PMID: 20973886 DOI: 10.1111/j.1872-034X.2010.00737.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
507 Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ; Hepatitis B Foundation. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010;52:2192-205. [PMID: 20890947 DOI: 10.1002/hep.23934] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 8.5] [Reference Citation Analysis]
508 Ma J, Guo X, Wu X, Li J, Zhu X, Li Z, Li J, Pan L, Li T, Li H, Liu Y. Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population. J Med Virol 2010;82:1501-7. [PMID: 20648603 DOI: 10.1002/jmv.21855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
509 Santos AO, Alvarado-Mora MV, Botelho L, Vieira DS, Pinho JR, Carrilho FJ, Honda ER, Salcedo JM. Characterization of hepatitis B virus (HBV) genotypes in patients from Rondônia, Brazil. Virol J 2010;7:315. [PMID: 21073730 DOI: 10.1186/1743-422X-7-315] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
510 Fiel MI. Pathology of chronic hepatitis B and chronic hepatitis C. Clin Liver Dis 2010;14:555-75. [PMID: 21055682 DOI: 10.1016/j.cld.2010.07.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
511 Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol. 2010;30:546-555. [PMID: 20393789 DOI: 10.1007/s10875-010-9416-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 5.0] [Reference Citation Analysis]
512 Pang R, Tao J, Zhang S, Zhao L, Yue X, Wang Y, Ye P, Dong J, Zhu Y, Wu J. In vitro antiviral activity of lutein against hepatitis B virus. Phytother Res 2010;24:1627-30. [DOI: 10.1002/ptr.3155] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
513 Fung J, Lai CL, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther. 2010;8:717-726. [PMID: 20521898 DOI: 10.1586/eri.10.45] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
514 Croagh CM, Bell SJ, Slavin J, Kong YX, Chen RY, Locarnini S, Desmond PV. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int 2010;30:1115-22. [PMID: 20492511 DOI: 10.1111/j.1478-3231.2010.02267.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
515 McMahon BJ. Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life. Gastroenterology 2010;139:380-2. [PMID: 20600063 DOI: 10.1053/j.gastro.2010.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
516 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381-96. [PMID: 20638020 DOI: 10.1016/j.cld.2010.05.007] [Cited by in Crossref: 126] [Cited by in F6Publishing: 125] [Article Influence: 9.7] [Reference Citation Analysis]
517 Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D. Autoantibodies against tumor-related antigens: Incidence and biologic significance. Human Immunology 2010;71:643-51. [DOI: 10.1016/j.humimm.2010.03.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
518 Gu Y, Zhao J, Yao XM, Li Y. Effects of bicyclol on immunological liver fibrosis in rats. J Asian Nat Prod Res. 2010;12:388-398. [PMID: 20496196 DOI: 10.1080/10286021003789047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
519 Lim JK, Ayoub WS, Nguyen MH. Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. Curr Hepatitis Rep 2010;9:65-74. [DOI: 10.1007/s11901-010-0040-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
520 Keating GM. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs 2009;69:2633-60. [PMID: 19943712 DOI: 10.2165/11203660-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
521 Wang CX, Lu YQ, Qi P, Chen LH, Han JX. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus. Virol J 2010;7:61. [PMID: 20236514 DOI: 10.1186/1743-422X-7-61] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
522 Pang R, Tao J, Zhang S, Zhu J, Yue X, Zhao L, Ye P, Zhu Y. In vitro anti-hepatitis B virus effect of Hypericum perforatum L. J Huazhong Univ Sci Technol [Med Sci ] 2010;30:98-102. [DOI: 10.1007/s11596-010-0118-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
523 McMahon BJ. Recent advances in managing hepatitis B. F1000 Med Rep 2010;2:11. [PMID: 20948875 DOI: 10.3410/M2-11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
524 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol. 2009;15:5761-5769. [PMID: 19998495 DOI: 10.3748/wjg.15.5761.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
525 Mizokami M, Tanaka E, Chayama K, Tanaka Y, Kurosaki M, Izumi N, Arase Y, Kumada H, Imazeki F, Yokosuka O, Kudo M. JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. Acta hepatologica Japonica 2010;51:243-260. [DOI: 10.2957/kanzo.51.243] [Reference Citation Analysis]
526 Koeberlein B, zur Hausen A, Bektas N, Zentgraf H, Chin R, Nguyen LT, Kandolf R, Torresi J, Bock CT. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res. 2010;148:51-59. [PMID: 20005910 DOI: 10.1016/j.virusres.2009.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
527 Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis 2009;1:e2009028. [PMID: 21415996 DOI: 10.4084/MJHID.2009.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 0.8] [Reference Citation Analysis]
528 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15(46): 5761-5769 [PMID: 19998495 DOI: 10.3748/wjg.15.5761] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 119] [Article Influence: 7.2] [Reference Citation Analysis]
529 Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW. New developments in antiviral therapy for chronic hepatitis B. Vox Sang. 2010;98:481-494. [PMID: 19951307 DOI: 10.1111/j.1423-0410.2009.01282.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
530 Brunetto M. New therapeutic approaches for long-term control of chronic hepatitis B. Digestive and Liver Disease Supplements 2009;3:67-70. [DOI: 10.1016/s1594-5804(09)60025-5] [Reference Citation Analysis]
531 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
532 Howell JA, Visvanathan K. A novel role for human leukocyte antigen-DP in chronic hepatitis B infection: a genomewide association study. Hepatology 2009;50:647-9. [PMID: 19642163 DOI: 10.1002/hep.23147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
533 Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21. [PMID: 19399811 DOI: 10.1002/hep.22881] [Cited by in Crossref: 539] [Cited by in F6Publishing: 539] [Article Influence: 38.5] [Reference Citation Analysis]
534 Kitamura T. Recent Advances in Hepatitis B Research. Juntendo Medical Journal 2009;55:443-449. [DOI: 10.14789/pjmj.55.443] [Reference Citation Analysis]